Tenet Healthcare (THC) 10-Q 4 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Jul. 31, 2014
Document and Entity Information	'	'
Entity Registrant Name	'TENET HEALTHCARE CORP	'
Entity Central Index Key	'0000070318	'
Document Type	'10-Q	'
Document Period End Date	30-Jun-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	97,915,606
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$406	$113
Accounts receivable, less allowance for doubtful accounts ($753 at June 30, 2014 and $589 at December 31, 2013)	2,171	1,965
Inventories of supplies, at cost	264	262
Income tax receivable	34	0
Current portion of deferred income taxes	633	581
Other current assets	700	789
Total current assets	4,208	3,710
Investments and other assets	362	405
Deferred income taxes, net of current portion	125	90
Property and equipment, at cost, less accumulated depreciation and amortization ($4,178 at June 30, 2014 and $3,898 at December 31, 2013)	7,771	7,691
Goodwill	3,200	3,042
Other intangible assets, at cost, less accumulated amortization ($618 at June 30, 2014 and $523 at December 31, 2013)	1,241	1,192
Total assets	16,907	16,130
Current liabilities:	'	'
Current portion of long-term debt	622	149
Accounts payable	1,015	1,075
Accrued compensation and benefits	669	631
Professional and general liability reserves	162	156
Accrued interest payable	207	198
Other current liabilities	709	719
Total current liabilities	3,384	2,928
Long-term debt, net of current portion	10,942	10,690
Professional and general liability reserves	567	543
Defined benefit plan obligations	380	398
Other long-term liabilities	484	446
Total liabilities	15,757	15,005
Commitments and contingencies	'	'
Redeemable noncontrolling interests in equity of consolidated subsidiaries	277	247
Shareholders' equity:	'	'
Common stock, $0.05 par value; authorized 262,500,000 shares; 145,010,828 shares issued at June 30, 2014 and 144,057,351 shares issued at December 31, 2013	7	7
Additional paid-in capital	4,594	4,572
Accumulated other comprehensive loss	-20	-24
Accumulated deficit	-1,480	-1,422
Common stock in treasury, at cost, 47,196,972 shares at June 30, 2014 and 47,197,722 shares at December 31, 2013	-2,378	-2,378
Total shareholders' equity	723	755
Noncontrolling interests	150	123
Total equity	873	878
Total liabilities and equity	$16,907	$16,130

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Millions, except Share data, unless otherwise specified
CONDENSED CONSOLIDATED BALANCE SHEETS	'	'
Accounts receivable, allowance for doubtful accounts (in dollars)	$753	$589
Property and equipment, accumulated depreciation and amortization (in dollars)	4,178	3,898
Other intangible assets, accumulated amortization (in dollars)	$618	$523
Common stock, par value (in dollars per share)	$0.05	$0.05
Common stock, authorized shares	262,500,000	262,500,000
Common stock, shares issued	145,010,828	144,057,351
Common stock in treasury, shares	47,196,972	47,197,722

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		6 Months Ended
In Millions, except Share data in Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Net operating revenues:	'	'	'	'
Net operating revenues before provision for doubtful accounts	$4,362	$2,629	$8,668	$5,223
Less: Provision for doubtful accounts	320	207	700	414
Net operating revenues	4,042	2,422	7,968	4,809
Operating expenses:	'	'	'	'
Salaries, wages and benefits	1,956	1,166	3,877	2,327
Supplies	649	387	1,277	771
Other operating expenses, net	1,035	567	2,034	1,135
Electronic health record incentives	-58	-34	-67	-34
Depreciation and amortization	209	121	402	235
Impairment and restructuring charges, and acquisition-related costs	32	11	53	25
Litigation and investigation costs	12	2	15	2
Operating income	207	202	377	348
Interest expense	-190	-98	-372	-201
Loss from early extinguishment of debt	0	-171	0	-348
Investment earnings	0	1	0	1
Income (loss) from continuing operations, before income taxes	17	-66	5	-200
Income tax benefit (expense)	-8	20	-7	73
Income (loss) from continuing operations, before discontinued operations	9	-46	-2	-127
Discontinued operations:	'	'	'	'
Income (loss) from operations	-7	6	-15	3
Litigation and investigation costs	-18	0	-18	0
Income tax benefit (expense)	9	-3	12	-2
Income (loss) from discontinued operations	-16	3	-21	1
Net loss	-7	-43	-23	-126
Less: Net income attributable to noncontrolling interests	19	7	35	12
Net loss attributable to Tenet Healthcare Corporation common shareholders	-26	-50	-58	-138
Amounts attributable to Tenet Healthcare Corporation common shareholders	'	'	'	'
Loss from continuing operations, net of tax	-10	-53	-37	-139
Income (loss) from discontinued operations, net of tax	-16	3	-21	1
Net loss attributable to Tenet Healthcare Corporation common shareholders	($26)	($50)	($58)	($138)
Basic	'	'	'	'
Continuing operations (in dollars per share)	($0.11)	($0.52)	($0.38)	($1.34)
Discontinued operations (in dollars per share)	($0.16)	$0.03	($0.22)	$0.01
Total earnings (loss) per share, Basic (in dollars per share)	($0.27)	($0.49)	($0.60)	($1.33)
Diluted	'	'	'	'
Continuing operations (in dollars per share)	($0.11)	($0.52)	($0.38)	($1.34)
Discontinued operations (in dollars per share)	($0.16)	$0.03	($0.22)	$0.01
Total earnings (loss) per share, Diluted (in dollars per share)	($0.27)	($0.49)	($0.60)	($1.33)
Weighted average shares and dilutive securities outstanding (in thousands):	'	'	'	'
Basic (in shares)	97,677	103,010	97,419	103,557
Diluted (in shares)	97,677	103,010	97,419	103,557

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE INCOME (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
CONDENSED CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE INCOME	'	'	'	'
Net loss	($7)	($43)	($23)	($126)
Other comprehensive income:	'	'	'	'
Amortization of prior-year service costs included in net periodic benefit costs	2	0	3	0
Unrealized gains on securities held as available-for-sale	3	0	3	0
Other comprehensive income before income taxes	5	0	6	0
Income tax expense related to items of other comprehensive income	-2	0	-2	0
Total other comprehensive income, net of tax	3	0	4	0
Comprehensive net loss	-4	-43	-19	-126
Less: Comprehensive income attributable to noncontrolling interests	19	7	35	12
Comprehensive net loss attributable to Tenet Healthcare Corporation common shareholders	($23)	($50)	($54)	($138)

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS	'	'
Net loss	($23)	($126)
Adjustments to reconcile net loss to net cash provided by operating activities:	'	'
Depreciation and amortization	402	235
Provision for doubtful accounts	700	414
Deferred income tax benefit	-7	-76
Stock-based compensation expense	26	19
Impairment and restructuring charges, and acquisition-related costs	53	25
Litigation and investigation costs	15	2
Loss from early extinguishment of debt	0	348
Amortization of debt discount and debt issuance costs	14	9
Pre-tax (income) loss from discontinued operations	33	-3
Other items, net	-9	-18
Changes in cash from operating assets and liabilities:	'	'
Accounts receivable	-937	-445
Inventories and other current assets	78	-166
Income taxes	-17	-4
Accounts payable, accrued expenses and other current liabilities	-32	-65
Other long-term liabilities	47	5
Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements	-84	-19
Net cash used in operating activities from discontinued operations, excluding income taxes	-12	-7
Net cash provided by operating activities	247	128
Cash flows from investing activities:	'	'
Purchases of property and equipment - continuing operations	-523	-256
Purchases of businesses or joint venture interests, net of cash acquired	-42	-16
Proceeds from sales of marketable securities, long-term investments and other assets	3	3
Other long-term assets	-14	6
Other items, net	0	3
Net cash used in investing activities	-576	-260
Cash flows from financing activities:	'	'
Repayments of borrowings under credit facility	-1,300	-620
Proceeds from borrowings under credit facility	895	653
Repayments of other borrowings	-68	-1,967
Proceeds from other borrowings	1,108	1,907
Repurchases of common stock	0	-192
Deferred debt issuance costs	-19	-30
Distributions paid to noncontrolling interests	-20	-10
Contributions from noncontrolling interests	13	98
Proceeds from exercise of stock options	11	21
Other items, net	2	-2
Net cash provided by (used in) financing activities	622	-142
Net increase (decrease) in cash and cash equivalents	293	-274
Cash and cash equivalents at beginning of period	113	364
Cash and cash equivalents at end of period	406	90
Supplemental disclosures:	'	'
Interest paid, net of capitalized interest	-360	-226
Income tax payments, net	($19)	($8)

BASIS_OF_PRESENTATION

BASIS OF PRESENTATION	6 Months Ended
	Jun. 30, 2014
BASIS OF PRESENTATION	'
BASIS OF PRESENTATION	'
	NOTE 1. BASIS OF PRESENTATION
	Description of Business and Basis of Presentation
	Tenet Healthcare Corporation (together with our subsidiaries, referred to herein as “Tenet,” “we” or “us”) is a national, diversified healthcare services company. As of June 30, 2014, we operated 79 hospitals, 189 outpatient centers, six health plans and Conifer Health Solutions, LLC (“Conifer”), which provides healthcare business process services in the areas of revenue cycle management, value-based care and patient communications.
	Effective October 1, 2013, we acquired the common stock of Vanguard Health Systems, Inc. (“Vanguard”) for $21 per share in an all cash transaction. Vanguard owned and operated 28 hospitals (plus one more under construction, which was recently completed), 39 outpatient centers and five health plans with approximately 140,000 members, serving communities in Arizona, California, Illinois, Massachusetts, Michigan and Texas. We paid approximately $4.3 billion to acquire Vanguard, including the assumption of $2.5 billion of Vanguard’s net debt.
	This quarterly report supplements our Annual Report on Form 10-K for the year ended December 31, 2013 (“Annual Report”). As permitted by the Securities and Exchange Commission for interim reporting, we have omitted certain notes and disclosures that substantially duplicate those in our Annual Report. For further information, refer to the audited Consolidated Financial Statements and notes included in our Annual Report. Unless otherwise indicated, all financial and statistical data included in these notes to our Condensed Consolidated Financial Statements relate to our continuing operations, with dollar amounts expressed in millions (except per-share amounts). Certain prior-year amounts have been adjusted to conform to the current-year presentation, including $73 million of Medicaid supplemental payments receivable that are now presented as other current assets rather than accounts receivable.
	Although the Condensed Consolidated Financial Statements and related notes within this document are unaudited, we believe all adjustments considered necessary for a fair presentation have been included and are of a normal recurring nature. In preparing our financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”), we must use estimates and assumptions that affect the amounts reported in our Condensed Consolidated Financial Statements and these accompanying notes. We regularly evaluate the accounting policies and estimates we use. In general, we base the estimates on historical experience and on assumptions that we believe to be reasonable given the particular circumstances in which we operate. Actual results may vary from those estimates. Financial and statistical information we report to other regulatory agencies may be prepared on a basis other than GAAP or using different assumptions or reporting periods and, therefore, may vary from amounts presented herein. Although we make every effort to ensure that the information we report to those agencies is accurate, complete and consistent with applicable reporting guidelines, we cannot be responsible for the accuracy of the information they make available to the public.
	Operating results for the three and six month periods ended June 30, 2014 are not necessarily indicative of the results that may be expected for the full year. Reasons for this include, but are not limited to: overall revenue and cost trends, particularly the timing and magnitude of price changes; fluctuations in contractual allowances and cost report settlements and valuation allowances; managed care contract negotiations, settlements or terminations and payer consolidations; changes in Medicare and Medicaid regulations; Medicaid and other supplemental funding levels set by the states in which we operate; the timing of approval by the Centers for Medicare and Medicaid Services of Medicaid provider fee revenue programs; trends in patient accounts receivable collectability and associated provisions for doubtful accounts; fluctuations in interest rates; levels of malpractice insurance expense and settlement trends; the number of covered lives managed by our health plans and the plans’ ability to effectively manage medical costs; the timing of when we meet the criteria to recognize electronic health record incentives; impairment of long-lived assets and goodwill; restructuring charges; losses, costs and insurance recoveries related to natural disasters; litigation and investigation costs; acquisitions and dispositions of facilities and other assets; income tax rates and deferred tax asset valuation allowance activity; changes in estimates of accruals for annual incentive compensation; the timing and amounts of stock option and restricted stock unit grants to employees and directors; gains or losses from early extinguishment of debt; and changes in occupancy levels and patient volumes. Factors that affect patient volumes and, thereby, the results of operations at our hospitals and related healthcare facilities include, but are not limited to: the business environment, economic conditions and demographics of local communities in which we operate; the number of uninsured and underinsured individuals in local communities treated at our hospitals; seasonal cycles of illness; climate and weather conditions; physician recruitment, retention and attrition; advances in technology and treatments that reduce length of stay; local healthcare competitors; managed care contract negotiations or terminations; any unfavorable publicity about us, which impacts our relationships with physicians and patients; changes in healthcare regulations and the participation of individual states in federal programs; and the timing of elective procedures. These considerations apply to year-to-year comparisons as well.
	Net Operating RevenuesBefore Provision for Doubtful Accounts
	We recognize net operating revenues before provision for doubtful accounts in the period in which our services are performed. Net operating revenues before provision for doubtful accounts primarily consist of net patient service revenues that are recorded based on established billing rates (i.e., gross charges), less estimated discounts for contractual and other allowances, principally for patients covered by Medicare, Medicaid, managed care and other health plans, as well as certain uninsured patients under ourCompact with Uninsured Patients (“Compact”) and other uninsured discount and charity programs.
	The table below shows the sources of net operating revenues before provision for doubtful accounts:
		Three Months Ended					Six Months Ended
		June 30,					June 30,
		2014		2013			2014		2013
	General Hospitals:
	Medicare	$	865	$	502		$	1,722	$	1,042
	Medicaid	380		236			672		424
	Managed care	2,228		1,387			4,418		2,748
	Indemnity, self-pay and other	368		261			815		521
	Acute care hospitals — other revenue	18		11			37		39
	Other:
	Other operations	503		232			1,004		449
	Net operating revenues before provision for doubtful accounts	$	4,362	$	2,629		$	8,668	$	5,223
	Cash and Cash Equivalents
	We treat highly liquid investments with original maturities of three months or less as cash equivalents. Cash and cash equivalents were approximately $406 million and $113 million at June 30, 2014 and December 31, 2013, respectively. As of June 30, 2014 and December 31, 2013, our book overdrafts were approximately $144 million and $245 million, respectively, which were classified as accounts payable.
	At June 30, 2014 and December 31, 2013, approximately $79 million and $62 million, respectively, of total cash and cash equivalents in the accompanying Condensed Consolidated Balance Sheets were intended for the operations of our captive insurance subsidiaries.
	Also at June 30, 2014 and December 31, 2013, we had $114 million and $193 million, respectively, of property and equipment purchases accrued for items received but not yet paid. Of these amounts, $64 million and $138 million, respectively, were included in accounts payable.
	During the six months ended June 30, 2014 and 2013, we entered into non-cancellable capital leases of approximately $60 million and $79 million, respectively, primarily for buildings and equipment.
	Other Intangible Assets
	The following table provides information regarding other intangible assets, which are included in the accompanying Condensed Consolidated Balance Sheets as of June 30, 2014 and December 31, 2013:
		Gross		Accumulated			Net Book
		Carrying		Amortization			Value
		Amount
	As of June 30, 2014:
	Capitalized software costs	$	1,385	$	(546	)	$	839
	Long-term debt issuance costs	247		(44		)	203
	Trade names	81		0			81
	Contracts	64		(6		)	58
	Other	82		(22		)	60
	Total	$	1,859	$	(618	)	$	1,241
		Gross		Accumulated			Net Book
		Carrying		Amortization			Value
		Amount
	As of December 31, 2013:
	Capitalized software costs	$	1,260	$	(475	)	$	785
	Long-term debt issuance costs	230		(31		)	199
	Trade names	81		0			81
	Contracts	64		(2		)	62
	Other	80		(15		)	65
	Total	$	1,715	$	(523	)	$	1,192
	Estimated future amortization of intangibles with finite useful lives as of June 30, 2014 is as follows:
				Years Ending December 31,											Later
		Total		2014			2015		2016		2017		2018		Years
	Amortization of intangible assets	$	1,151	$	128		$	241	$	188	$	128	$	124	$	342

ACCOUNTS_RECEIVABLE_AND_ALLOWA

ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS	6 Months Ended
	Jun. 30, 2014
ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS	'
ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS	'
	NOTE 2. ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS
	The principal components of accounts receivable are shown in the table below:
		June 30,			December 31,
		2014			2013
	Continuing operations:
	Patient accounts receivable	$	2,949		$	2,537
	Allowance for doubtful accounts	(753		)	(589		)
	Estimated future recoveries from accounts assigned to our Conifer subsidiary	90			91
	Net cost reports and settlements payable and valuation allowances	(118		)	(77		)
		2,168			1,962
	Discontinued operations	3			3
	Accounts receivable, net	$	2,171		$	1,965
	As of June 30, 2014 and December 31, 2013, our allowance for doubtful accounts was 25.5% and 23.2%, respectively, of our patient accounts receivable. The increase in the provision for doubtful accounts primarily related to a decrease in our self-pay collection rate, as well as higher patient co-pays and deductibles, partially offset by decreased uninsured patient revenues, in the six months ended June 30, 2014. Accounts that are pursued for collection through Conifer’s regional business offices are maintained on our hospitals’ books and reflected in patient accounts receivable with an allowance for doubtful accounts established to reduce the carrying value of such receivables to their estimated net realizable value. Generally, we estimate this allowance based on the aging of our accounts receivable by hospital, our historical collection experience by hospital and for each type of payer, and other relevant factors. As of June 30, 2014 and December 31, 2013, our allowance for doubtful accounts for self-pay was 76.5% and 75.9%, respectively, of our self-pay patient accounts receivable, including co-pays and deductibles owed by patients with insurance. As of June 30, 2014 and December 31, 2013, our allowance for doubtful accounts for managed care was 5.7% and 5.6%, respectively, of our managed care patient accounts receivable.
	The estimated costs (based on selected operating expenses, which include salaries, wages and benefits, supplies and other operating expenses) of caring for our self-pay patients for the three months ended June 30, 2014 and 2013 were approximately $167 million and $122 million, respectively, and for the six months ended June 30, 2014 and 2013 were approximately $353 million and $226 million, respectively. Our estimated costs (based on the selected operating expenses described above) of caring for charity care patients for the three months ended June 30, 2014 and 2013 were approximately $55 million and $31 million, respectively, and for the six months ended June 30, 2014 and 2013 were approximately $95 million and $63 million, respectively. Most states include an estimate of the cost of charity care in the determination of a hospital’s eligibility for Medicaid disproportionate share hospital (“DSH”) payments. Revenues attributable to DSH payments and other state-funded subsidy payments for the three months ended June 30, 2014 and 2013 were approximately $157 million and $119 million, respectively, and for the six months ended June 30, 2014 and 2013 were approximately $311 million and $186 million, respectively. These payments are intended to mitigate our cost of uncompensated care, as well as reduced Medicaid funding levels.

DISCONTINUED_OPERATIONS

DISCONTINUED OPERATIONS	6 Months Ended
	Jun. 30, 2014
DISCONTINUED OPERATIONS	'
DISCONTINUED OPERATIONS	'
	NOTE 3. DISCONTINUED OPERATIONS
	Net operating revenues and income (loss) before income taxes reported in discontinued operations are as follows:
		Three Months Ended					Six Months Ended
		June 30,					June 30,
		2014			2013		2014			2013
	Net operating revenues	$	0		$	0	$	1		$	3
	Income (loss) before income taxes	(25		)	6		(33		)	3
	Included in loss before income taxes from discontinued operations in the three months ended June 30, 2014 is approximately $18 million of expense recorded in litigation and investigation costs allocable to one of our previously divested hospitals related to a class action lawsuit discussed in Note 10. In the three months ended June 30, 2013, we recognized a $7 million gain in discontinued operations related to the sale of land.
	Should we dispose of additional hospitals or other assets in the future, we may incur asset impairment and restructuring charges in future periods.

IMPAIRMENT_AND_RESTRUCTURING_C

IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS	6 Months Ended
	Jun. 30, 2014
IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS	'
IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS	'
	NOTE 4. IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS
	During the six months ended June 30, 2014, we recorded impairment and restructuring charges and acquisition-related costs of $53 million, consisting $9 million of employee severance costs, $18 million of restructuring costs, and $26 million in acquisition-related costs, which include $4 million of transaction costs and $22 million of acquisition integration charges.
	During the six months ended June 30, 2013, we recorded impairment and restructuring charges and acquisition-related costs of $25 million, consisting of $2 million relating to the impairment of property, $7 million of restructuring costs, $5 million of employee severance costs, $1 million of lease termination costs, and $10 million in acquisition-related costs.
	Our impairment tests presume stable, improving or, in some cases, declining operating results in our hospitals, which are based on programs and initiatives being implemented that are designed to achieve the hospital’s most recent projections. If these projections are not met, or if in the future negative trends occur that impact our future outlook, impairments of long-lived assets and goodwill may occur, and we may incur additional restructuring charges, which could be material.
	As of June 30, 2014, our continuing operations consisted of two operating segments, our hospital and other operations and our Conifer subsidiary. During the three months ended March 31, 2014, we combined our California region and our Phoenix market to form our Western region. Our hospital and other operations are currently structured as follows:
	·        Our Central region includes all of our hospitals and other operations in Missouri, New Mexico, Tennessee and Texas, except for those in the San Antonio and South Texas markets;
	·        Our Florida region includes all of our hospitals and other operations in Florida;
	·        Our Northeast region includes all of our hospitals and other operations in Illinois, Massachusetts and Pennsylvania;
	·        Our Southern region includes all of our hospitals and other operations in Alabama, Georgia, North Carolina and South Carolina;
	·        Our Western region includes all of our hospitals and other operations in Arizona and California;
	·        Our Detroit market includes all of our hospitals and other operations in the Detroit, Michigan area;
	·        Our San Antonio market includes all of our hospitals and other operations in the San Antonio, Texas area;
	·        Our South Texas market includes all of our hospitals and other operations in the Brownsville and Harlingen, Texas areas; and
	·        Our Resolute Health market includes our hospital and other operations in the New Braunfels, Texas area.
	These regions and markets are reporting units used to perform our goodwill impairment analysis and are one level below our hospital operations reportable business segment level.
	We periodically incur costs to implement restructuring efforts for specific operations, which are recorded in our statement of operations as they are incurred. Our restructuring plans focus on various aspects of operations, including aligning our operations in the most strategic and cost-effective structure. Certain restructuring and acquisition-related costs are based on estimates. Changes in estimates are recognized as they occur.

LONGTERM_DEBT_AND_LEASE_OBLIGA

LONG-TERM DEBT AND LEASE OBLIGATIONS	6 Months Ended
	Jun. 30, 2014
LONG-TERM DEBT AND LEASE OBLIGATIONS	'
LONG-TERM DEBT AND LEASE OBLIGATIONS	'
	NOTE 5. LONG-TERM DEBT AND LEASE OBLIGATIONS
	The table below shows our long-term debt as of June 30, 2014 and December 31, 2013:
		June 30,			December 31,
		2014			2013
	Senior notes:
	97¤8%, due 2014	$	60		$	60
	91¤4%, due 2015	474			474
	5%, due 2019	1,100			0
	63¤4%, due 2020	300			300
	8%, due 2020	750			750
	81/8%, due 2022	2,800			2,800
	67¤8%, due 2031	430			430
	Senior secured notes:
	61¤4%, due 2018	1,041			1,041
	43/4%, due 2020	500			500
	6%, due 2020	1,800			1,800
	41/2%, due 2021	850			850
	43/8%, due 2021	1,050			1,050
	Credit facility due 2016	0			405
	Capital leases and mortgage notes	428			407
	Unamortized note discounts and premium	(19		)	(28		)
	Total long-term debt	11,564			10,839
	Less current portion	622			149
	Long-term debt, net of current portion	$	10,942		$	10,690
	Credit Agreement
	We have a senior secured revolving credit facility (as amended, “Credit Agreement”) that provides, subject to borrowing availability, for revolving loans in an aggregate principal amount of up to $1 billion, with a $300 million subfacility for standby letters of credit. The Credit Agreement, which has a scheduled maturity date of November 29, 2016, is collateralized by patient accounts receivable of all of our wholly owned acute care and specialty hospitals. In addition, borrowings under the Credit Agreement are guaranteed by our wholly owned hospital subsidiaries. Outstanding revolving loans accrue interest at a base rate plus a margin ranging from 1.00% to 1.50% or the London Interbank Offered Rate plus a margin ranging from 2.00% to 2.50% per annum based on available credit. An unused commitment fee payable on the undrawn portion of the revolving loans ranges from 0.375% to 0.500% per annum based on available credit. Our borrowing availability is based on a specified percentage of eligible accounts receivable, including self-pay accounts. At June 30, 2014, we had no cash borrowings outstanding under the revolving credit facility; however, we had approximately $6 million of standby letters of credit outstanding. Based on our eligible receivables, approximately $994 million was available for borrowing under the revolving credit facility at June 30, 2014.
	Letter of Credit Facility
	On March 7, 2014, we entered into a new letter of credit facility agreement (“LC Facility”) that provides for the issuance of standby and documentary letters of credit (including certain letters of credit issued under our existing Credit Agreement, which we transferred to the LC Facility (the “Existing Letters of Credit”)), from time to time, in an aggregate principal amount of up to $180 million (subject to increase to up to $200 million). The LC Facility has a scheduled maturity date of March 7, 2017, and obligations thereunder are guaranteed by and secured by a first priority pledge of the capital stock and other ownership interests of certain of our hospital subsidiaries on an equal ranking basis with our existing senior secured notes.
	Drawings under any letter of credit issued under the LC Facility (including the Existing Letters of Credit) that we have not reimbursed within three business days after notice thereof will accrue interest at a base rate plus a margin equal to 0.875% per annum. An unused commitment fee is payable at an initial rate of 0.50% per annum with a step down to 0.375% per annum based on the secured debt to EBITDA ratio of 3.00 to 1.00. A per annum fee on the aggregate outstanding amount of issued but undrawn letters of credit (including Existing Letters of Credit) will accrue at a rate of 1.875% per annum. An issuance fee equal to 0.125% per annum of the aggregate face amount of each outstanding letter of credit is payable to the account of the issuer of the related letter of credit. At June 30, 2014, we had approximately $133 million of standby letters of credit outstanding under the LC Facility.
	Senior Notes
	In June and March 2014, we sold $500 million and $600 million aggregate principal amount, respectively, of 5% senior notes, which will mature on March 1, 2019. We will pay interest on the notes semi-annually in arrears on March 1 and September 1 of each year, commencing on September 1, 2014. The net proceeds from the sale of the notes in June 2014 were used to redeem our 91/4% senior notes due 2015 in July 2014. The proceeds from the sale of the notes in March 2014 were used for general corporate purposes, including the repayment of borrowings under our Credit Agreement.
	All of our senior notes are general unsecured senior debt obligations that rank equally in right of payment with all of our other unsecured senior indebtedness, but are effectively subordinated to our senior secured notes described in our Annual Report, the obligations of our subsidiaries, and any obligations under our Credit Agreement and the LC Facility to the extent of the collateral. Our Annual Report also describes the covenants and conditions, as well as other provisions, including our redemption rights, set forth in the indentures governing our senior notes.

GUARANTEES

GUARANTEES	6 Months Ended
	Jun. 30, 2014
GUARANTEES	'
GUARANTEES	'
	NOTE 6. GUARANTEES
	At June 30, 2014, the maximum potential amount of future payments under our income guarantees to certain physicians who agree to relocate and revenue collection guarantees to hospital-based physician groups providing certain services at our hospitals was $94 million. We had a liability of $69 million recorded for these guarantees included in other current liabilities at June 30, 2014.
	We have also guaranteed minimum rent revenue to certain landlords who built medical office buildings on or near our hospital campuses. The maximum potential amount of future payments under these guarantees at June 30, 2014 was $4 million. We had a liability of less than $1 million recorded for these guarantees included in other current liabilities at June 30, 2014.

EMPLOYEE_BENEFIT_PLANS

EMPLOYEE BENEFIT PLANS	6 Months Ended
	Jun. 30, 2014
EMPLOYEE BENEFIT PLANS	'
EMPLOYEE BENEFIT PLANS	'
	NOTE 7. EMPLOYEE BENEFIT PLANS
	At June 30, 2014, approximately 6.0 million shares of common stock were available under our 2008 Stock Incentive Plan for future stock option grants and other incentive awards, including restricted stock units. Options have an exercise price equal to the fair market value of the shares on the date of grant and generally expire 10 years from the date of grant. A restricted stock unit is a contractual right to receive one share of our common stock or the equivalent value in cash in the future. Options and restricted stock units typically vest one-third on each of the first three anniversary dates of the grant; however, from time to time, we grant (i) options and restricted stock units with different time-based vesting terms, and (ii) performance-based options and restricted stock units that vest subject to the achievement of specified performance goals within a specified timeframe.
	Our income from continuing operations for the six months ended June 30, 2014 and 2013 includes $26 million and $22 million, respectively, of pre-tax compensation costs related to our stock-based compensation arrangements.
	Stock Options
	The following table summarizes stock option activity during the six months ended June 30, 2014:
		Options		Weighted Average			Aggregate			Weighted Average
				Exercise Price			Intrinsic Value			Remaining Life
				Per Share
							(In Millions)
	Outstanding as of December 31, 2013	3,308,111		$	30.79
	Granted	0
	Exercised	(336,789	)	34.08
	Forfeited/Expired	(620,719	)	47.96
	Outstanding as of June 30, 2014	2,350,603		$	25.78		$	50		3.8 years
	Vested and expected to vest at June 30, 2014	2,340,428		$	25.73		$	50		3.8 years
	Exercisable as of June 30, 2014	1,932,972		$	24.03		$	44		3.5 years
	There were 336,789 stock options exercised during the six months ended June 30, 2014 with a $4 million aggregate intrinsic value, and 875,005 stock options exercised during the same period in 2013 with a $16 million aggregate intrinsic value.
	As of June 30, 2014, there were $3 million of total unrecognized compensation costs related to stock options. These costs are expected to be recognized over a weighted average period of 1.3 years.
	There were no stock options granted in the six months ended June 30, 2014. In the six months ended June 30, 2013, we granted an aggregate of 295,639 stock options under our 2008 Stock Incentive Plan to certain of our senior officers. These stock options will all vest on the third anniversary of the grant date, subject to the terms of the Plan, and will expire on the fifth anniversary of the grant date.
	The weighted average estimated fair value of stock options we granted in the six months ended June 30, 2013 was $14.46 per share. This fair value was calculated based on the grant date, using a binomial lattice model with the following assumptions:
		Six Months Ended
		June 30, 2013
	Expected volatility	50%
	Expected dividend yield	0%
	Expected life	3.6 years
	Expected forfeiture rate	6%
	Risk-free interest rate	0.48%
	Early exercise threshold	100% gain
	Early exercise rate	50% per year
	The expected volatility used in the binomial lattice model incorporated historical and implied share-price volatility and was based on an analysis of historical prices of our stock and open-market exchanged options. The expected volatility reflects the historical volatility for a duration consistent with the contractual life of the options, and the volatility implied by the trading of options to purchase our stock on open-market exchanges. The historical share-price volatility excludes the movements in our stock price on two dates (one in 2010 and one in 2011) with unusual volatility due to an unsolicited acquisition proposal. The expected life of options granted is derived from the output of the binomial lattice model and represents the period of time that the options are expected to be outstanding. This model incorporates an early exercise assumption in the event of a significant increase in stock price. The risk-free interest rates are based on zero-coupon United States Treasury yields in effect at the date of grant consistent with the expected exercise timeframes.
	The following table summarizes information about our outstanding stock options at June 30, 2014:
		Options Outstanding							Options Exercisable
	Range of Exercise Prices	Number of		Weighted Average		Weighted Average			Number of		Weighted Average
		Options		Remaining		Exercise Price			Options		Exercise Price
				Contractual Life
	$0.00 to $4.569	279,719		4.6 years		$	4.56		279,719		$	4.56
	$4.57 to $25.089	1,010,431		5.4 years		20.89			871,251		20.55
	$25.09 to $32.569	453,862		2.1 years		29.38			453,862		29.38
	$32.57 to $42.529	595,009		2.1 years		40.87			316,558		42.24
	$42.53 to $55.129	11,582		0.7 years		49.17			11,582		49.17
		2,350,603		3.8 years		$	25.78		1,932,972		$	24.03
	Restricted Stock Units
	The following table summarizes restricted stock unit activity during the six months ended June 30, 2014:
		Restricted Stock		Weighted Average Grant
		Units		Date Fair Value Per Unit
	Unvested as of December 31, 2013	2,707,222		$	33.34
	Granted	1,280,028		44.36
	Vested	(884,431	)	30.18
	Forfeited	(119,020	)	33.68
	Unvested as of June 30, 2014	2,983,799		$	38.04
	In the six months ended June 30, 2014, we granted 1,280,028 restricted stock units subject to time-vesting of which 944,590 will vest and be settled ratably over a three-year period from the date of the grant, 52,971 will vest 100% on the fifth anniversary of the grant date and 10,652 will vest 100% on the third anniversary of the grant date. In addition, we granted 271,815 performance-based restricted stock units to certain of our senior officers; the vesting of these restricted stock units is contingent on our achievement of a specified one-year performance goal for the year ending December 31, 2014. Provided the goal is achieved, the performance-based restricted stock units will vest ratably over a three-year period from the grant date. If the performance goal is not achieved, the restricted stock units will be forfeited. The actual number of performance-based restricted stock units that could vest will range from 0% to 200% of the 271,815 units granted, depending on our level of achievement with respect to the performance goal.
	In the six months ended June 30, 2013, we granted 804,062 restricted stock units subject to time-vesting, of which 723,929 will vest and be settled ratably over a three-year period from the grant date and 80,133 will vest 100% on the fifth anniversary of the grant date. In addition, we granted 206,058 performance-based restricted stock units to certain of our senior officers. Because the performance goal for the year ended December 31, 2013 was met at the target level, 100% of the performance-based restricted stock units will vest and be settled ratably over a three-year period from the grant date. We also awarded a grant of 212,180 restricted stock units to our chief executive officer, of which 106,090 are subject to time-vesting and 106,090 are performance-based. If target conditions are met, 50% of this grant will vest three years from the grant date and the remaining 50% will vest six years from the grant date. The award also allows for an additional 106,090 shares to be issued if higher performance criteria are met.
	As of June 30, 2014, there were $94 million of total unrecognized compensation costs related to restricted stock units. These costs are expected to be recognized over a weighted average period of 2.6 years.

EQUITY

EQUITY	6 Months Ended
	Jun. 30, 2014
EQUITY	'
EQUITY	'
	NOTE 8. EQUITY
	Changes in Shareholders’ Equity
	The following table shows the changes in consolidated equity during the six months ended June 30, 2014 and 2013 (dollars in millions, share amounts in thousands):
		Tenet Healthcare Corporation Shareholders’ Equity
									Accumulated
		Common Stock					Additional		Other
		Shares		Issued Par			Paid-in		Comprehensive			Accumulated			Treasury			Noncontrolling			Total Equity
		Outstanding		Amount			Capital		Loss			Deficit			Stock			Interests
	Balances at December 31, 2013	96,860		$	7		$	4,572	$	(24	)	$	(1,422	)	$	(2,378	)	$	123		$	878
	Net income (loss)	0		0			0		0			(58		)	0			13			(45		)
	Distributions paid to noncontrolling interests	0		0			0		0			0			0			(18		)	(18		)
	Contributions from noncontrolling interests	0		0			0		0			0			0			3			3
	Other comprehensive income	0		0			0		4			0			0			0			4
	Purchases of businesses or joint venture interests	0		0			0		0			0			0			29			29
	Stock-based compensation expense and issuance of common stock	954		0			22		0			0			0			0			22
	Balances at June 30, 2014	97,814		$	7		$	4,594	$	(20	)	$	(1,480	)	$	(2,378	)	$	150		$	873
	Balances at December 31, 2012	104,633		$	7		$	4,471	$	(68	)	$	(1,288	)	$	(1,979	)	$	75		$	1,218
	Net income (loss)	0		0			0		0			(138		)	0			8			(130		)
	Distributions paid to noncontrolling interests	0		0			0		0			0			0			(10		)	(10		)
	Sale of joint venture interest	0		0			53		0			0			0			0			53
	Purchases of businesses or joint venture interests	0		0			0		0			0			0			13			13
	Repurchase of common stock	(4,453	)	0			0		0			0			(192		)	0			(192		)
	Stock-based compensation expense and issuance of common stock	1,558		0			28		0			0			1			0			29
	Balances at June 30, 2013	101,738		$	7		$	4,552	$	(68	)	$	(1,426	)	$	(2,170	)	$	86		$	981
	Changes in Redeemable Noncontrolling Interests in Equity of Consolidated Subsidiaries
	The following table shows the changes in redeemable noncontrolling interests in equity of consolidated subsidiaries during the six months ended June 30, 2014 and 2013:
		Six Months Ended June 30,
		2014			2013
	Balances at beginning of period	$	247		$	16
	Net income	22			4
	Distributions paid to noncontrolling interests	(2		)	0
	Contributions from noncontrolling interests	10			0
	Sales of joint venture interests	0			50
	Purchases of businesses	0			10
	Balances at end of period	$	277		$	80

PROPERTY_AND_PROFESSIONAL_AND_

PROPERTY AND PROFESSIONAL AND GENERAL LIABILITY INSURANCE	6 Months Ended
	Jun. 30, 2014
PROPERTY AND PROFESSIONAL AND GENERAL LIABILITY INSURANCE	'
PROPERTY AND PROFESSIONAL AND GENERAL LIABILITY INSURANCE	'
	NOTE 9. PROPERTY AND PROFESSIONAL AND GENERAL LIABILITY INSURANCE
	Property Insurance
	We have property, business interruption and related insurance coverage to mitigate the financial impact of catastrophic events or perils that is subject to deductible provisions based on the terms of the policies. These policies are on an occurrence basis.
	Professional and General Liability Reserves
	At June 30, 2014 and December 31, 2013, the aggregate current and long-term professional and general liability reserves in our accompanying Condensed Consolidated Balance Sheets were approximately $729 million and $699 million, respectively. These reserves include the reserves recorded by our captive insurance subsidiaries and our self-insured retention reserves recorded based on actuarial estimates for the portion of our professional and general liability risks, including incurred but not reported claims, for which we do not have insurance coverage. We estimated the reserves for losses and related expenses using expected loss-reporting patterns discounted to their present value under a risk-free rate approach using a Federal Reserve seven-year maturity rate of 2.13% and 2.45% at June 30, 2014 and December 31, 2013, respectively.
	If the aggregate limit of any of our professional and general liability policies is exhausted, in whole or in part, it could deplete or reduce the limits available to pay any other material claims applicable to that policy period.
	Included in other operating expenses, net, in the accompanying Condensed Consolidated Statements of Operations is malpractice expense of $127 million and $52 million for the six months ended June 30, 2014 and 2013, respectively.

CLAIMS_AND_LAWSUITS

CLAIMS AND LAWSUITS	6 Months Ended
	Jun. 30, 2014
CLAIMS AND LAWSUITS	'
CLAIMS AND LAWSUITS	'
	NOTE 10. CLAIMS AND LAWSUITS
	We operate in a highly regulated and litigious industry. As a result, we commonly become involved in disputes, litigation and regulatory matters incidental to our operations, including governmental investigations, personal injury lawsuits, employment claims and other matters arising out of the normal conduct of our business.
	We record accruals for estimated losses relating to claims and lawsuits when available information indicates that a loss is probable and we can reasonably estimate the amount of the loss or a range of loss. If a loss on a material matter is reasonably possible and estimable, we disclose an estimate of the loss or a range of loss. In cases where we have not disclosed an estimate, we have concluded that the loss is either not reasonably possible or the loss, or a range of loss, is not reasonably estimable, based on available information.
	Governmental Reviews
	Healthcare companies are subject to numerous investigations by various governmental agencies. Further, private parties have the right to bring qui tam or “whistleblower” lawsuits against companies that allegedly submit false claims for payments to, or improperly retain overpayments from, the government and, in some states, private payers. Certain of our individual facilities have received inquiries from government agencies, and our facilities may receive such inquiries in future periods. The following material governmental reviews, which have been previously reported, are currently pending.
	·         Kyphoplasty—From March 2009 through July 2010, seven of our hospitals became the subject of a review by the U.S. Department of Justice (“DOJ”) and certain other federal agencies regarding the appropriateness of inpatient treatment for Medicare patients receiving kyphoplasty, which is a surgical procedure used to treat certain spinal conditions. We believe this review is part of a national investigation and is related to a qui tam settlement between the government and the manufacturer and distributor of Kyphon, the product used in performing kyphoplasty procedures. In January 2013, we paid $900,000 to settle claims against one of our hospitals subject to this review, and, in April 2014, we confirmed that another hospital is no longer the subject of investigation. We continue to engage in settlement discussions with the DOJ to resolve this matter with respect to the remaining five hospitals. Although it is impossible to predict the ultimate outcome of those discussions, we believe it is possible that a settlement could be reached in the year ending December 31, 2014. Furthermore, based on current discussions, we believe the amount of the reserve management has established for this matter, as described below, continues to reflect our current estimate of probable liability.
	·         Implantable Cardioverter Defibrillators (“ICDs”)—At this time, 56 of our hospitals are part of a nationwide investigation to determine whether ICD procedures from 2002 to 2010 complied with Medicare coverage requirements. In August 2012, the DOJ released its “Medical Review Guidelines/Resolution Model,” which sets out, for purposes of this investigation, the patient conditions and criteria for the medical necessity of the implantation of ICDs in Medicare beneficiaries and how the DOJ will enforce the repayment obligations of hospitals. Management has established a reserve, as described below, to reflect the current estimate of probable liability for all of the hospitals under review as part of the government’s examination, which commenced in March 2010. We are engaged in potential settlement discussions with the DOJ to resolve this matter, but it is impossible at this time to predict the outcome of those discussions or the amount of any potential resolution.
	·         Clinica de la Mama Investigations and Qui Tam Action—As previously reported, we received a subpoena in May 2012 from the Office of Inspector General (“OIG”) of U.S. Department of Health and Human Services in Atlanta seeking documents from January 2004 through May 2012 related to the relationship that certain of our Georgia and South Carolina hospitals had with Hispanic Medical Management, Inc. (“HMM”). HMM was an unaffiliated entity that owned and operated clinics that provided, among other things, prenatal care predominantly to uninsured patients. The hospitals contracted with HMM for translation, marketing, management and Medicaid eligibility determination services. The civil investigation is being conducted by the Civil Division of the DOJ, the U.S. Attorney’s Office for the Middle District of Georgia and the Georgia Attorney General’s Office, while the parallel criminal investigation is being conducted by the Criminal Division of the DOJ and the U.S. Attorney’s Office for the Northern District of Georgia.
	The investigations arose out of a qui tam action captioned United States of America, ex. rel. Ralph D. Williams v. Health Management Associates, Inc., et al. filed in the U.S. District Court for the Middle District of Georgia. Tenet and four of its hospital subsidiaries are defendants in the qui tam action, which alleges that the arrangements the hospitals had with HMM violated the federal and state anti-kickback statutes and false claims acts. Both the Georgia Attorney General’s Office, on behalf of the State of Georgia, and the U.S. Attorney’s Office, on behalf of the United States, have intervened in the qui tam action. We submitted answers to the complaints filed by the relator, the State of Georgia and the United States on July 15, 2014 following the court’s denial of our motions to dismiss in June 2014. On July 25, 2014, the civil court granted the United States' unopposed motion to stay discovery in the case.
	If we or our subsidiaries were determined to have violated the anti-kickback statutes, the government could require us to reimburse related government program payments received during the subject period, assess civil monetary penalties including treble damages, exclude individuals or subsidiaries from participation in federal healthcare programs, or seek criminal sanctions against current or former employees of our hospital subsidiary companies or the hospital companies themselves. In a Bill of Information filed on July 23, 2014 with the U.S. District Court for the Northern District of Georgia, Atlanta Division, the U.S. Attorney for that District asserted charges of one count of criminal conspiracy against a former owner of HMM (a non-employee of Tenet) related to the agreements between HMM and the Tenet hospitals described above. In a separate Bill of Information also filed with the court on July 23, 2014, the U.S. Attorney asserted charges of one count of criminal conspiracy against a former employee of a Tenet hospital, but such charges relate to an unaffiliated entity. Management has established a reserve, as described below, to reflect the current estimate of probable liability for these matters, but it is impossible at this time to predict the amount and terms of any potential resolution. We will continue to vigorously defend against the government’s allegations.
	Except with respect to the matter settled in January 2013 involving one hospital, as discussed above, our analysis of each of these pending reviews is still ongoing, and we are unable to predict with any certainty the progress or final outcome of any discussions with government agencies at this time. Based on currently available information, we increased our reserves by approximately $10 million in the three months ended June 30, 2014, resulting in recorded reserves of approximately $38 million in the aggregate for our potential reimbursement obligations with respect to all of the hospitals under review for their billing practices for kyphoplasty and cardiac defibrillator implantation procedures, as well as the Clinica de la Mama matters. Changes in the reserves may be required in the future as additional information becomes available. We cannot predict the ultimate resolution of any governmental review, and the final amounts paid in settlement or otherwise, if any, could differ materially from our currently recorded reserves.
	Ordinary Course Matters
	We are also subject to other claims and lawsuits arising in the ordinary course of business, including potential claims related to, among other things, the care and treatment provided at our hospitals and outpatient facilities, the application of various federal and state labor laws, tax audits and other matters. Although the results of these claims and lawsuits cannot be predicted with certainty, we believe that the ultimate resolution of these ordinary course claims and lawsuits will not have a material effect on our business, financial condition or results of operations.
	In addition, in June 2014, we agreed on principal terms to settle a previously disclosed class action lawsuit captioned Doe, et al. v. Jo Ellen Smith Medical Foundation, which was filed in the Civil District Court for the Parish of Orleans in Louisiana in March 1997. The plaintiffs pursued a claim for tortious invasion of privacy due to the fact that in April 1996 patient identifying records from a psychiatric hospital we closed in 1995 were temporarily placed in an unsecure location while the hospital was undergoing renovations. The court certified a class of over 5,000 persons; however, only eight individuals (in addition to the two plaintiffs) have been identified to date in the class certification process. The plaintiffs have asserted each member of the class is entitled to common damages under a theory of presumed “common damage” regardless of whether or not any members of the class were actually harmed or even aware of the incident. In an effort to avoid protracted litigation, the parties settled this matter in June 2014 for a maximum potential payment of $32.5 million, subject to the number and type of claims asserted by the class members. The settlement, which will be funded in amounts and on a schedule to be agreed to by the parties, is subject to execution of a final agreement and court approval. In the three months ended June 30, 2014, we established a reserve of $17 million, recorded in discontinued operations, to reflect our current estimate of probable liability for this matter based on anticipated levels of class member participation.
	New claims or inquiries may be initiated against us from time to time. These matters could (1) require us to pay substantial damages or amounts in judgments or settlements, which individually or in the aggregate could exceed amounts, if any, that may be recovered under our insurance policies where coverage applies and is available, (2) cause us to incur substantial expenses, (3) require significant time and attention from our management, and (4) cause us to close or sell hospitals or otherwise modify the way we conduct business.
	The table below presents reconciliations of the beginning and ending liability balances in connection with legal settlements and related costs recorded during the six months ended June 30, 2014 and 2013:
		Balances at		Litigation and		Cash			Other			Balances at
		Beginning		Investigation		Payments						End of
		of Period		Costs								Period
	Six Months Ended June 30, 2014
	Continuing operations	$	40	$	15	$	(6	)	$	(3	)	$	46
	Discontinued operations	6		18		(6		)	0			18
		$	46	$	33	$	(12	)	$	(3	)	$	64
	Six Months Ended June 30, 2013
	Continuing operations	$	5	$	2	$	(2	)	$	0		$	5
	Discontinued operations	5		0		(1		)	0			4
		$	10	$	2	$	(3	)	$	0		$	9
	For the six months ended June 30, 2014 and 2013, we recorded costs of $33 million and $2 million, respectively, primarily related to costs associated with various legal proceedings and governmental reviews.

INCOME_TAXES

INCOME TAXES	6 Months Ended
	Jun. 30, 2014
INCOME TAXES	'
INCOME TAXES	'
	NOTE 11. INCOME TAXES
	During the six months ended June 30, 2014, we recorded income tax expense of $7 million, which includes $3 million to increase our valuation allowance for deferred tax assets. The increase in the valuation allowance relates to an estimated decrease in the future utilization of state net operating loss carryovers.
	During the six months ended June 30, 2014, there were no adjustments to our estimated liabilities for uncertain tax positions. The total amount of unrecognized tax benefits as of June 30, 2014 was $43 million, of which $34 million, if recognized, would impact our effective tax rate and income tax expense (benefit) from continuing operations.
	Our practice is to recognize interest and penalties related to income tax matters in income tax expense in our consolidated statements of operations. Total accrued interest and penalties on unrecognized tax benefits as of June 30, 2014 were $5 million, all of which related to continuing operations.
	As of June 30, 2014, approximately $1 million of unrecognized federal and state tax benefits, as well as reserves for interest and penalties, may decrease in the next 12 months as a result of the settlement of audits, the filing of amended tax returns or the expiration of statutes of limitations.

EARNINGS_LOSS_PER_COMMON_SHARE

EARNINGS (LOSS) PER COMMON SHARE	6 Months Ended
	Jun. 30, 2014
EARNINGS (LOSS) PER COMMON SHARE	'
EARNINGS (LOSS) PER COMMON SHARE	'
	NOTE 12. EARNINGS (LOSS) PER COMMON SHARE
	The table below is a reconciliation of the numerators and denominators of our basic and diluted loss per common share calculations for net loss from continuing operations for the three and six months ended June 30, 2014 and 2013. Net loss is expressed in millions and weighted average shares are expressed in thousands.
		Net Loss			Weighted	Per-Share
		(Numerator)			Average	Amount
					Shares
					(Denominator)
	Three Months Ended June 30, 2014
	Net loss attributable to Tenet Healthcare Corporation common shareholders for basic earnings per share	$	(10	)	97,677	$	(0.11	)
	Effect of dilutive stock options and restricted stock units	0			0	0
	Net loss attributable to Tenet Healthcare Corporation common shareholders for diluted earnings per share	$	(10	)	97,677	$	(0.11	)
	Three Months Ended June 30, 2013
	Net loss attributable to Tenet Healthcare Corporation common shareholders for basic earnings per share	$	(53	)	103,010	$	(0.52	)
	Effect of dilutive stock options and restricted stock units	0			0	0
	Net loss attributable to Tenet Healthcare Corporation common shareholders for diluted earnings per share	$	(53	)	103,010	$	(0.52	)
	Six Months Ended June 30, 2014
	Net loss attributable to Tenet Healthcare Corporation common shareholders for basic earnings per share	$	(37	)	97,419	$	(0.38	)
	Effect of dilutive stock options and restricted stock units	0			0	0
	Net loss attributable to Tenet Healthcare Corporation common shareholders for diluted earnings per share	$	(37	)	97,419	$	(0.38	)
	Six Months Ended June 30, 2013
	Net loss attributable to Tenet Healthcare Corporation common shareholders for basic earnings per share	$	(139	)	103,557	$	(1.34	)
	Effect of dilutive stock options and restricted stock units	0			0	0
	Net loss attributable to Tenet Healthcare Corporation common shareholders for diluted earnings per share	$	(139	)	103,557	$	(1.34	)
	All potentially dilutive securities were excluded from the calculation of diluted loss per share for the three and six months ended June 30, 2014 and 2013 because we did not report income from continuing operations available to shareholders in those periods. In circumstances where we do not have income from continuing operations available to shareholders, the effect of stock options and other potentially dilutive securities is anti-dilutive, that is, a loss from continuing operations available to shareholders has the effect of making the diluted loss per share less than the basic loss per share. Had we generated income from continuing operations available to shareholders in those periods, the effect (in thousands) of employee stock options, restricted stock units and deferred compensation units on the diluted shares calculation would have been an increase in shares of 2,123 and 2,053 for the three and six months ended June 30, 2014, respectively, and 2,326 and 2,282 for the three and six months ended June 30, 2013, respectively.

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS	6 Months Ended
	Jun. 30, 2014
FAIR VALUE MEASUREMENTS	'
FAIR VALUE MEASUREMENTS	'
	NOTE 13. FAIR VALUE MEASUREMENTS
	Our financial assets and liabilities recorded at fair value on a recurring basis primarily relate to investments in available-for-sale securities held by our captive insurance subsidiaries. The following tables present information about our assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2014 and December 31, 2013. The following tables also indicate the fair value hierarchy of the valuation techniques we utilized to determine such fair values. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. We consider a security that trades at least weekly to have an active market. Fair values determined by Level 2 inputs utilize data points that are observable, such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability.
	Investments:	June 30, 2014		Quoted Prices		Significant Other		Significant
				in Active		Observable Inputs		Unobservable
				Markets for		(Level 2)		Inputs
				Identical Assets				(Level 3)
				(Level 1)
	Marketable securities — current	$	2	$	2	$	0	$	0
	Investments in Reserve Yield Plus Fund	2		0		2		0
	Marketable debt securities — noncurrent	66		27		38		1
		$	70	$	29	$	40	$	1
	Investments:	December 31, 2013		Quoted Prices		Significant Other		Significant
				in Active		Observable Inputs		Unobservable
				Markets for		(Level 2)		Inputs
				Identical Assets				(Level 3)
				(Level 1)
	Marketable securities — current	$	1	$	1	$	0	$	0
	Investments in Reserve Yield Plus Fund	2		0		2		0
	Marketable debt securities — noncurrent	62		23		38		1
		$	65	$	24	$	40	$	1
	The fair value of our long-term debt is based on quoted market prices (Level 1). At June 30, 2014 and December 31, 2013, the estimated fair value of our long-term debt was approximately 107.6% and 103.5%, respectively, of the carrying value of the debt.

ACQUISITIONS

ACQUISITIONS	6 Months Ended
	Jun. 30, 2014
ACQUISITIONS	'
ACQUISITIONS	'
	NOTE 14. ACQUISITIONS
	During the six months ended June 30, 2014, we acquired a majority interest in Texas Regional Medical Center at Sunnyvale, a 70-bed hospital in Sunnyvale, Texas, a suburban community east of Dallas. We also acquired three ambulatory surgery centers, three urgent care centers, one diagnostic imaging center and various physician practice entities in the same period. The fair value of the consideration conveyed in the acquisitions (the “purchase price”) was $42 million.
	We are required to allocate the purchase prices of the acquired businesses to assets acquired or liabilities assumed and, if applicable, noncontrolling interests based on their fair values. The excess of the purchase price allocation over those fair values is recorded as goodwill. We are in process of finalizing the purchase price allocations, including valuations of the acquired property and equipment primarily for several recent acquisitions; therefore, those purchase price allocations are subject to adjustment once the valuations are completed. During the six months ended June 30, 2014, we made adjustments to purchase price allocations for businesses acquired in 2013 that increased goodwill by approximately $87 million due to additional information received during the period.
	Preliminary purchase price allocations for the acquisitions made during the six months ended June 30, 2014 are as follows:
	Current assets	$	14
	Property and equipment	19
	Goodwill	71
	Current liabilities	(16		)
	Long-term liabilities	(17		)
	Noncontrolling interests	(29		)
	Net cash paid	$	42
	The goodwill generated from these transactions, a significant portion of which will not be deductible for income tax purposes, can be attributed to the benefits that we expect to realize from operating efficiencies and increased reimbursement.
	Approximately $4 million in transaction costs related to prospective and closed acquisitions were expensed during the six months ended June 30, 2014, and are included in impairment and restructuring charges, and acquisition-related costs in the accompanying Condensed Consolidated Statement of Operations.
	Pro Forma Information - Unaudited
	The following table provides certain pro forma financial information for Tenet as if the Vanguard acquisition had occurred at the beginning of the year ended December 31, 2013.
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014		2013
	Net operating revenues	$	4,042		$	3,940		$	7,968	$	7,826
	Income (loss) from continuing operations, before income taxes	$	17		$	(66	)	$	5	$	(198	)

SEGMENT_INFORMATION

SEGMENT INFORMATION	6 Months Ended
	Jun. 30, 2014
SEGMENT INFORMATION	'
SEGMENT INFORMATION	'
	NOTE 15. SEGMENT INFORMATION
	Our core business is hospital operations and other, which is focused on owning and operating acute care hospitals and outpatient facilities. We also own various related healthcare businesses. At June 30, 2014, our subsidiaries operated 79 hospitals, with a total of 20,553 licensed beds, primarily serving urban and suburban communities, as well as 189 outpatient centers and six health plans.
	We operate revenue cycle management and patient communications and engagement services businesses under our Conifer subsidiary. In addition, Conifer operates a management services business that supports value-based performance through clinical integration, financial risk management and population health management. At June 30, 2014, Conifer provided services to more than 700 Tenet and non-Tenet hospital and other clients nationwide. Conifer’s two largest customers, Tenet and Catholic Health Initiatives, together comprised 82% and 79% of Conifer’s net operating revenues for the six months ended June 30, 2014 and 2013, respectively.
	The following table includes amounts for each of our reportable segments and the reconciling items necessary to agree to amounts reported in the accompanying Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Operations:
		June 30,			December 31,
		2014			2013
	Assets:
	Hospital operations and other	$	16,577		$	15,874
	Conifer	330			256
	Total	$	16,907		$	16,130
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014			2013
	Capital expenditures:
	Hospital operations and other	$	237		$	117		$	510		$	248
	Conifer	5			6			13			8
	Total	$	242		$	123		$	523		$	256
	Net operating revenues:
	Hospital operations and other	$	3,895		$	2,297		$	7,676		$	4,565
	Conifer
	Tenet	138			94			278			186
	Other customers	147			125			292			244
		4,180			2,516			8,246			4,995
	Intercompany eliminations	(138		)	(94		)	(278		)	(186		)
	Total	$	4,042		$	2,422		$	7,968		$	4,809
		Three Months Ended						Six Months Ended
		June 30,						June 30,
	Adjusted EBITDA:
	Hospital operations and other	$	416		$	308		$	755		$	550
	Conifer	44			28			92			60
	Total	$	460		$	336		$	847		$	610
	Depreciation and amortization:
	Hospital operations and other	$	204		$	115		$	392		$	225
	Conifer	5			6			10			10
	Total	$	209		$	121		$	402		$	235
	Adjusted EBITDA	$	460		$	336		$	847		$	610
	Depreciation and amortization	(209		)	(121		)	(402		)	(235		)
	Impairment and restructuring charges, and acquisition-related costs	(32		)	(11		)	(53		)	(25		)
	Litigation and investigation costs	(12		)	(2		)	(15		)	(2		)
	Interest expense	(190		)	(98		)	(372		)	(201		)
	Loss from early extinguishment of debt	0			(171		)	0			(348		)
	Investment earnings	0			1			0			1
	Income (loss) from continuing operations before income taxes	$	17		$	(66	)	$	5		$	(200	)

RECENTLY_ISSUED_ACCOUNTING_STA

RECENTLY ISSUED ACCOUNTING STANDARDS	6 Months Ended
	Jun. 30, 2014
RECENTLY ISSUED ACCOUNTING STANDARDS	'
RECENTLY ISSUED ACCOUNTING STANDARDS	'
	NOTE 16. RECENTLY ISSUED ACCOUNTING STANDARDS
	In April 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-08, “Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity” (“ASU 2014-08”). ASU 2014-08 changes the requirements for reporting discontinued operations in FASB Accounting Standards Codification Subtopic 205-20, such that a disposal of a component of an entity or a group of components of an entity is required to be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results. ASU 2014-08 requires an entity to present, for each comparative period, the assets and liabilities of a disposal group that includes a discontinued operation separately in the asset and liability sections, respectively, of the statement of financial position, as well as additional disclosures about discontinued operations. Additionally, ASU 2014-08 requires disclosures about a disposal of an individually significant component of an entity that does not qualify for discontinued operations presentation in the financial statements and expands the disclosures about an entity’s significant continuing involvement with a discontinued operation. We are currently evaluating the potential impact of this guidance, which will be effective for us beginning in 2015.
	In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”). ASU 2014-09 affects any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards. The core principle of the guidance in ASU 2014-09 is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. We are currently evaluating the potential impact of this guidance, which will be effective for us beginning in 2017.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2014
SUBSEQUENT EVENTS	'
SUBSEQUENT EVENTS	'
	NOTE 17. SUBSEQUENT EVENTS
	In July 2014, we used the net proceeds from the sale of our 5% senior notes due 2019 to redeem approximately $474 million aggregate principal amount outstanding of our 91/4% senior notes due 2015. In connection with the redemption, we will record a loss from early extinguishment of debt of approximately $24 million, primarily related to the difference between the purchase price and the par value of the notes, as well as the write-off of associated unamortized note discounts and issuance costs.

BASIS_OF_PRESENTATION_Policies

BASIS OF PRESENTATION (Policies)	6 Months Ended
	Jun. 30, 2014
BASIS OF PRESENTATION	'
Net Operating Revenues Before Provision for Doubtful Accounts	'
	Net Operating RevenuesBefore Provision for Doubtful Accounts
	We recognize net operating revenues before provision for doubtful accounts in the period in which our services are performed. Net operating revenues before provision for doubtful accounts primarily consist of net patient service revenues that are recorded based on established billing rates (i.e., gross charges), less estimated discounts for contractual and other allowances, principally for patients covered by Medicare, Medicaid, managed care and other health plans, as well as certain uninsured patients under ourCompact with Uninsured Patients (“Compact”) and other uninsured discount and charity programs.
	The table below shows the sources of net operating revenues before provision for doubtful accounts:
		Three Months Ended					Six Months Ended
		June 30,					June 30,
		2014		2013			2014		2013
	General Hospitals:
	Medicare	$	865	$	502		$	1,722	$	1,042
	Medicaid	380		236			672		424
	Managed care	2,228		1,387			4,418		2,748
	Indemnity, self-pay and other	368		261			815		521
	Acute care hospitals — other revenue	18		11			37		39
	Other:
	Other operations	503		232			1,004		449
	Net operating revenues before provision for doubtful accounts	$	4,362	$	2,629		$	8,668	$	5,223
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	We treat highly liquid investments with original maturities of three months or less as cash equivalents. Cash and cash equivalents were approximately $406 million and $113 million at June 30, 2014 and December 31, 2013, respectively. As of June 30, 2014 and December 31, 2013, our book overdrafts were approximately $144 million and $245 million, respectively, which were classified as accounts payable.
	At June 30, 2014 and December 31, 2013, approximately $79 million and $62 million, respectively, of total cash and cash equivalents in the accompanying Condensed Consolidated Balance Sheets were intended for the operations of our captive insurance subsidiaries.
	Also at June 30, 2014 and December 31, 2013, we had $114 million and $193 million, respectively, of property and equipment purchases accrued for items received but not yet paid. Of these amounts, $64 million and $138 million, respectively, were included in accounts payable.
	During the six months ended June 30, 2014 and 2013, we entered into non-cancellable capital leases of approximately $60 million and $79 million, respectively, primarily for buildings and equipment.
Other Intangible Assets	'
	Other Intangible Assets
	The following table provides information regarding other intangible assets, which are included in the accompanying Condensed Consolidated Balance Sheets as of June 30, 2014 and December 31, 2013:
		Gross		Accumulated			Net Book
		Carrying		Amortization			Value
		Amount
	As of June 30, 2014:
	Capitalized software costs	$	1,385	$	(546	)	$	839
	Long-term debt issuance costs	247		(44		)	203
	Trade names	81		0			81
	Contracts	64		(6		)	58
	Other	82		(22		)	60
	Total	$	1,859	$	(618	)	$	1,241
		Gross		Accumulated			Net Book
		Carrying		Amortization			Value
		Amount
	As of December 31, 2013:
	Capitalized software costs	$	1,260	$	(475	)	$	785
	Long-term debt issuance costs	230		(31		)	199
	Trade names	81		0			81
	Contracts	64		(2		)	62
	Other	80		(15		)	65
	Total	$	1,715	$	(523	)	$	1,192
	Estimated future amortization of intangibles with finite useful lives as of June 30, 2014 is as follows:
				Years Ending December 31,											Later
		Total		2014			2015		2016		2017		2018		Years
	Amortization of intangible assets	$	1,151	$	128		$	241	$	188	$	128	$	124	$	342

BASIS_OF_PRESENTATION_Tables

BASIS OF PRESENTATION (Tables)	6 Months Ended
	Jun. 30, 2014
BASIS OF PRESENTATION	'
Schedule of sources of net operating revenues before provision for doubtful accounts	'
		Three Months Ended					Six Months Ended
		June 30,					June 30,
		2014		2013			2014		2013
	General Hospitals:
	Medicare	$	865	$	502		$	1,722	$	1,042
	Medicaid	380		236			672		424
	Managed care	2,228		1,387			4,418		2,748
	Indemnity, self-pay and other	368		261			815		521
	Acute care hospitals — other revenue	18		11			37		39
	Other:
	Other operations	503		232			1,004		449
	Net operating revenues before provision for doubtful accounts	$	4,362	$	2,629		$	8,668	$	5,223
Schedule of other intangible assets	'
		Gross		Accumulated			Net Book
		Carrying		Amortization			Value
		Amount
	As of June 30, 2014:
	Capitalized software costs	$	1,385	$	(546	)	$	839
	Long-term debt issuance costs	247		(44		)	203
	Trade names	81		0			81
	Contracts	64		(6		)	58
	Other	82		(22		)	60
	Total	$	1,859	$	(618	)	$	1,241
		Gross		Accumulated			Net Book
		Carrying		Amortization			Value
		Amount
	As of December 31, 2013:
	Capitalized software costs	$	1,260	$	(475	)	$	785
	Long-term debt issuance costs	230		(31		)	199
	Trade names	81		0			81
	Contracts	64		(2		)	62
	Other	80		(15		)	65
	Total	$	1,715	$	(523	)	$	1,192
Schedule of estimated future amortization of intangibles with finite useful lives	'
	Estimated future amortization of intangibles with finite useful lives as of June 30, 2014 is as follows:
				Years Ending December 31,											Later
		Total		2014			2015		2016		2017		2018		Years
	Amortization of intangible assets	$	1,151	$	128		$	241	$	188	$	128	$	124	$	342

ACCOUNTS_RECEIVABLE_AND_ALLOWA1

ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS (Tables)	6 Months Ended
	Jun. 30, 2014
ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS	'
Schedule Of Components Of Accounts Receivable	'
		June 30,			December 31,
		2014			2013
	Continuing operations:
	Patient accounts receivable	$	2,949		$	2,537
	Allowance for doubtful accounts	(753		)	(589		)
	Estimated future recoveries from accounts assigned to our Conifer subsidiary	90			91
	Net cost reports and settlements payable and valuation allowances	(118		)	(77		)
		2,168			1,962
	Discontinued operations	3			3
	Accounts receivable, net	$	2,171		$	1,965

DISCONTINUED_OPERATIONS_Tables

DISCONTINUED OPERATIONS (Tables)	6 Months Ended
	Jun. 30, 2014
DISCONTINUED OPERATIONS	'
Schedule of net operating revenues and income (loss) before income taxes	'
		Three Months Ended					Six Months Ended
		June 30,					June 30,
		2014			2013		2014			2013
	Net operating revenues	$	0		$	0	$	1		$	3
	Income (loss) before income taxes	(25		)	6		(33		)	3

LONGTERM_DEBT_AND_LEASE_OBLIGA1

LONG-TERM DEBT AND LEASE OBLIGATIONS (Tables)	6 Months Ended
	Jun. 30, 2014
LONG-TERM DEBT AND LEASE OBLIGATIONS	'
Summary of long-term debt	'
		June 30,			December 31,
		2014			2013
	Senior notes:
	97¤8%, due 2014	$	60		$	60
	91¤4%, due 2015	474			474
	5%, due 2019	1,100			0
	63¤4%, due 2020	300			300
	8%, due 2020	750			750
	81/8%, due 2022	2,800			2,800
	67¤8%, due 2031	430			430
	Senior secured notes:
	61¤4%, due 2018	1,041			1,041
	43/4%, due 2020	500			500
	6%, due 2020	1,800			1,800
	41/2%, due 2021	850			850
	43/8%, due 2021	1,050			1,050
	Credit facility due 2016	0			405
	Capital leases and mortgage notes	428			407
	Unamortized note discounts and premium	(19		)	(28		)
	Total long-term debt	11,564			10,839
	Less current portion	622			149
	Long-term debt, net of current portion	$	10,942		$	10,690

EMPLOYEE_BENEFIT_PLANS_Tables

EMPLOYEE BENEFIT PLANS (Tables)	6 Months Ended
	Jun. 30, 2014
EMPLOYEE BENEFIT PLANS	'
Summary of stock option activity	'
		Options		Weighted Average			Aggregate			Weighted Average
				Exercise Price			Intrinsic Value			Remaining Life
				Per Share
							(In Millions)
	Outstanding as of December 31, 2013	3,308,111		$	30.79
	Granted	0
	Exercised	(336,789	)	34.08
	Forfeited/Expired	(620,719	)	47.96
	Outstanding as of June 30, 2014	2,350,603		$	25.78		$	50		3.8 years
	Vested and expected to vest at June 30, 2014	2,340,428		$	25.73		$	50		3.8 years
	Exercisable as of June 30, 2014	1,932,972		$	24.03		$	44		3.5 years
Schedule of assumptions used to determine fair value of stock options	'
		Six Months Ended
		June 30, 2013
	Expected volatility	50%
	Expected dividend yield	0%
	Expected life	3.6 years
	Expected forfeiture rate	6%
	Risk-free interest rate	0.48%
	Early exercise threshold	100% gain
	Early exercise rate	50% per year
Summary of information about stock options by range of exercise prices	'
	The following table summarizes information about our outstanding stock options at June 30, 2014:
		Options Outstanding							Options Exercisable
	Range of Exercise Prices	Number of		Weighted Average		Weighted Average			Number of		Weighted Average
		Options		Remaining		Exercise Price			Options		Exercise Price
				Contractual Life
	$0.00 to $4.569	279,719		4.6 years		$	4.56		279,719		$	4.56
	$4.57 to $25.089	1,010,431		5.4 years		20.89			871,251		20.55
	$25.09 to $32.569	453,862		2.1 years		29.38			453,862		29.38
	$32.57 to $42.529	595,009		2.1 years		40.87			316,558		42.24
	$42.53 to $55.129	11,582		0.7 years		49.17			11,582		49.17
		2,350,603		3.8 years		$	25.78		1,932,972		$	24.03
Summary of restricted stock unit activity	'
		Restricted Stock		Weighted Average Grant
		Units		Date Fair Value Per Unit
	Unvested as of December 31, 2013	2,707,222		$	33.34
	Granted	1,280,028		44.36
	Vested	(884,431	)	30.18
	Forfeited	(119,020	)	33.68
	Unvested as of June 30, 2014	2,983,799		$	38.04

EQUITY_Tables

EQUITY (Tables)	6 Months Ended
	Jun. 30, 2014
EQUITY	'
Schedule Of Changes In Consolidated Equity	'
	The following table shows the changes in consolidated equity during the six months ended June 30, 2014 and 2013 (dollars in millions, share amounts in thousands):
		Tenet Healthcare Corporation Shareholders’ Equity
									Accumulated
		Common Stock					Additional		Other
		Shares		Issued Par			Paid-in		Comprehensive			Accumulated			Treasury			Noncontrolling			Total Equity
		Outstanding		Amount			Capital		Loss			Deficit			Stock			Interests
	Balances at December 31, 2013	96,860		$	7		$	4,572	$	(24	)	$	(1,422	)	$	(2,378	)	$	123		$	878
	Net income (loss)	0		0			0		0			(58		)	0			13			(45		)
	Distributions paid to noncontrolling interests	0		0			0		0			0			0			(18		)	(18		)
	Contributions from noncontrolling interests	0		0			0		0			0			0			3			3
	Other comprehensive income	0		0			0		4			0			0			0			4
	Purchases of businesses or joint venture interests	0		0			0		0			0			0			29			29
	Stock-based compensation expense and issuance of common stock	954		0			22		0			0			0			0			22
	Balances at June 30, 2014	97,814		$	7		$	4,594	$	(20	)	$	(1,480	)	$	(2,378	)	$	150		$	873
	Balances at December 31, 2012	104,633		$	7		$	4,471	$	(68	)	$	(1,288	)	$	(1,979	)	$	75		$	1,218
	Net income (loss)	0		0			0		0			(138		)	0			8			(130		)
	Distributions paid to noncontrolling interests	0		0			0		0			0			0			(10		)	(10		)
	Sale of joint venture interest	0		0			53		0			0			0			0			53
	Purchases of businesses or joint venture interests	0		0			0		0			0			0			13			13
	Repurchase of common stock	(4,453	)	0			0		0			0			(192		)	0			(192		)
	Stock-based compensation expense and issuance of common stock	1,558		0			28		0			0			1			0			29
	Balances at June 30, 2013	101,738		$	7		$	4,552	$	(68	)	$	(1,426	)	$	(2,170	)	$	86		$	981
Schedule of changes in redeemable noncontrolling interests in equity of consolidated subsidiaries	'
		Six Months Ended June 30,
		2014			2013
	Balances at beginning of period	$	247		$	16
	Net income	22			4
	Distributions paid to noncontrolling interests	(2		)	0
	Contributions from noncontrolling interests	10			0
	Sales of joint venture interests	0			50
	Purchases of businesses	0			10
	Balances at end of period	$	277		$	80

CLAIMS_AND_LAWSUITS_Tables

CLAIMS AND LAWSUITS (Tables)	6 Months Ended
	Jun. 30, 2014
CLAIMS AND LAWSUITS	'
Reconciliations Of Legal Settlements And Related Costs	'
		Balances at		Litigation and		Cash			Other			Balances at
		Beginning		Investigation		Payments						End of
		of Period		Costs								Period
	Six Months Ended June 30, 2014
	Continuing operations	$	40	$	15	$	(6	)	$	(3	)	$	46
	Discontinued operations	6		18		(6		)	0			18
		$	46	$	33	$	(12	)	$	(3	)	$	64
	Six Months Ended June 30, 2013
	Continuing operations	$	5	$	2	$	(2	)	$	0		$	5
	Discontinued operations	5		0		(1		)	0			4
		$	10	$	2	$	(3	)	$	0		$	9

EARNINGS_LOSS_PER_COMMON_SHARE1

EARNINGS (LOSS) PER COMMON SHARE (Tables)	6 Months Ended
	Jun. 30, 2014
EARNINGS (LOSS) PER COMMON SHARE	'
Schedule of reconciliation of numerators and denominators of our basic and diluted loss per common share	'
	Net loss is expressed in millions and weighted average shares are expressed in thousands.
		Net Loss			Weighted	Per-Share
		(Numerator)			Average	Amount
					Shares
					(Denominator)
	Three Months Ended June 30, 2014
	Net loss attributable to Tenet Healthcare Corporation common shareholders for basic earnings per share	$	(10	)	97,677	$	(0.11	)
	Effect of dilutive stock options and restricted stock units	0			0	0
	Net loss attributable to Tenet Healthcare Corporation common shareholders for diluted earnings per share	$	(10	)	97,677	$	(0.11	)
	Three Months Ended June 30, 2013
	Net loss attributable to Tenet Healthcare Corporation common shareholders for basic earnings per share	$	(53	)	103,010	$	(0.52	)
	Effect of dilutive stock options and restricted stock units	0			0	0
	Net loss attributable to Tenet Healthcare Corporation common shareholders for diluted earnings per share	$	(53	)	103,010	$	(0.52	)
	Six Months Ended June 30, 2014
	Net loss attributable to Tenet Healthcare Corporation common shareholders for basic earnings per share	$	(37	)	97,419	$	(0.38	)
	Effect of dilutive stock options and restricted stock units	0			0	0
	Net loss attributable to Tenet Healthcare Corporation common shareholders for diluted earnings per share	$	(37	)	97,419	$	(0.38	)
	Six Months Ended June 30, 2013
	Net loss attributable to Tenet Healthcare Corporation common shareholders for basic earnings per share	$	(139	)	103,557	$	(1.34	)
	Effect of dilutive stock options and restricted stock units	0			0	0
	Net loss attributable to Tenet Healthcare Corporation common shareholders for diluted earnings per share	$	(139	)	103,557	$	(1.34	)

FAIR_VALUE_MEASUREMENTS_Tables

FAIR VALUE MEASUREMENTS (Tables)	6 Months Ended
	Jun. 30, 2014
FAIR VALUE MEASUREMENTS	'
Schedule of assets and liabilities measured at fair value on a recurring basis	'
	Investments:	June 30, 2014		Quoted Prices		Significant Other		Significant
				in Active		Observable Inputs		Unobservable
				Markets for		(Level 2)		Inputs
				Identical Assets				(Level 3)
				(Level 1)
	Marketable securities — current	$	2	$	2	$	0	$	0
	Investments in Reserve Yield Plus Fund	2		0		2		0
	Marketable debt securities — noncurrent	66		27		38		1
		$	70	$	29	$	40	$	1
	Investments:	December 31, 2013		Quoted Prices		Significant Other		Significant
				in Active		Observable Inputs		Unobservable
				Markets for		(Level 2)		Inputs
				Identical Assets				(Level 3)
				(Level 1)
	Marketable securities — current	$	1	$	1	$	0	$	0
	Investments in Reserve Yield Plus Fund	2		0		2		0
	Marketable debt securities — noncurrent	62		23		38		1
		$	65	$	24	$	40	$	1

ACQUISITIONS_Tables

ACQUISITIONS (Tables)	6 Months Ended
	Jun. 30, 2014
ACQUISITIONS	'
Schedule of Preliminary purchase price allocations	'
	Preliminary purchase price allocations for the acquisitions made during the six months ended June 30, 2014 are as follows:
	Current assets	$	14
	Property and equipment	19
	Goodwill	71
	Current liabilities	(16		)
	Long-term liabilities	(17		)
	Noncontrolling interests	(29		)
	Net cash paid	$	42
Vanguard	'
Business Acquisition	'
Schedule of pro forma financial information as if the Vanguard Health Systems acquisition had occurred at the beginning of the year	'
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014		2013
	Net operating revenues	$	4,042		$	3,940		$	7,968	$	7,826
	Income (loss) from continuing operations, before income taxes	$	17		$	(66	)	$	5	$	(198	)

SEGMENT_INFORMATION_Tables

SEGMENT INFORMATION (Tables)	6 Months Ended
	Jun. 30, 2014
SEGMENT INFORMATION	'
Schedule of reconciliation of amounts for each reportable segments, Hospital Operations and other segment includes health plans, and the reconciling items	'
		June 30,			December 31,
		2014			2013
	Assets:
	Hospital operations and other	$	16,577		$	15,874
	Conifer	330			256
	Total	$	16,907		$	16,130
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014			2013
	Capital expenditures:
	Hospital operations and other	$	237		$	117		$	510		$	248
	Conifer	5			6			13			8
	Total	$	242		$	123		$	523		$	256
	Net operating revenues:
	Hospital operations and other	$	3,895		$	2,297		$	7,676		$	4,565
	Conifer
	Tenet	138			94			278			186
	Other customers	147			125			292			244
		4,180			2,516			8,246			4,995
	Intercompany eliminations	(138		)	(94		)	(278		)	(186		)
	Total	$	4,042		$	2,422		$	7,968		$	4,809
		Three Months Ended						Six Months Ended
		June 30,						June 30,
	Adjusted EBITDA:
	Hospital operations and other	$	416		$	308		$	755		$	550
	Conifer	44			28			92			60
	Total	$	460		$	336		$	847		$	610
	Depreciation and amortization:
	Hospital operations and other	$	204		$	115		$	392		$	225
	Conifer	5			6			10			10
	Total	$	209		$	121		$	402		$	235
	Adjusted EBITDA	$	460		$	336		$	847		$	610
	Depreciation and amortization	(209		)	(121		)	(402		)	(235		)
	Impairment and restructuring charges, and acquisition-related costs	(32		)	(11		)	(53		)	(25		)
	Litigation and investigation costs	(12		)	(2		)	(15		)	(2		)
	Interest expense	(190		)	(98		)	(372		)	(201		)
	Loss from early extinguishment of debt	0			(171		)	0			(348		)
	Investment earnings	0			1			0			1
	Income (loss) from continuing operations before income taxes	$	17		$	(66	)	$	5		$	(200	)

BASIS_OF_PRESENTATION_Details

BASIS OF PRESENTATION (Details) (USD $)

3 Months Ended

6 Months Ended

12 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

0 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Oct. 03, 2013

Oct. 01, 2013

item

Capitalized software costs

Capitalized software costs

Long-term debt issuance costs

Long-term debt issuance costs

Trade names

Trade names

Contracts

Contracts

Other

Other

Medicare

Medicare

Medicare

Medicare

Medicaid

Medicaid

Medicaid

Medicaid

Managed care

Managed care

Managed care

Managed care

Indemnity, self-pay and other

Indemnity, self-pay and other

Indemnity, self-pay and other

Indemnity, self-pay and other

Acute care hospitals - other revenue

Acute care hospitals - other revenue

Acute care hospitals - other revenue

Acute care hospitals - other revenue

Other operations

Other operations

Other operations

Other operations

Vanguard

Vanguard

item

Description of Business

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of acute care hospitals operated by subsidiaries

'

'

79

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of provider-based outpatient centers operated by subsidiaries

'

'

189

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of health plans

'

'

6

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Summary of significant accounting policies

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business acquisition share price (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$21

Number of hospitals

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

28

'

Number of hospitals under construction

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1

'

Number of outpatient centers

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

39

'

Number of health plans

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5

'

Number of members covered under the health plans

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

140,000

'

Cash paid

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$4,300,000,000

'

Assumed debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,500,000,000

Supplemental payments receivable recorded as other current assets rather than accounts receivable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

73,000,000

'

73,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net operating revenues before provision for doubtful accounts

4,362,000,000

2,629,000,000

8,668,000,000

5,223,000,000

'

'

'

'

'

'

'

'

'

'

'

'

865,000,000

502,000,000

1,722,000,000

1,042,000,000

380,000,000

236,000,000

672,000,000

424,000,000

2,228,000,000

1,387,000,000

4,418,000,000

2,748,000,000

368,000,000

261,000,000

815,000,000

521,000,000

18,000,000

11,000,000

37,000,000

39,000,000

503,000,000

232,000,000

1,004,000,000

449,000,000

'

'

Gross Carrying Amount

1,859,000,000

'

1,859,000,000

'

1,715,000,000

'

1,385,000,000

1,260,000,000

247,000,000

230,000,000

81,000,000

81,000,000

64,000,000

64,000,000

82,000,000

80,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accumulated Amortization

-618,000,000

'

-618,000,000

'

-523,000,000

'

-546,000,000

-475,000,000

-44,000,000

-31,000,000

0

0

-6,000,000

-2,000,000

-22,000,000

-15,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net Book Value

1,241,000,000

'

1,241,000,000

'

1,192,000,000

'

839,000,000

785,000,000

203,000,000

199,000,000

81,000,000

81,000,000

58,000,000

62,000,000

60,000,000

65,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash Equivalents

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash and cash equivalents

406,000,000

90,000,000

406,000,000

90,000,000

113,000,000

364,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Book overdrafts classified as accounts payable

144,000,000

'

144,000,000

'

245,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash and cash equivalents related to captive insurance subsidiaries

79,000,000

'

79,000,000

'

62,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued property and equipment purchases for items received but not yet paid

'

'

114,000,000

'

193,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued property and equipment purchases, for items received but not yet paid, included in accounts payable

64,000,000

'

64,000,000

'

138,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Non-cancellable capital leases primarily for buildings and equipment

'

'

$60,000,000

'

$79,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

BASIS_OF_PRESENTATION_Details_

BASIS OF PRESENTATION (Details 2) (USD $)	Jun. 30, 2014
In Millions, unless otherwise specified
Estimated future amortization of intangibles with finite useful lives	'
Net Book Value	$1,151
2014	128
2015	241
2016	188
2017	128
2018	124
Later Years	$342

ACCOUNTS_RECEIVABLE_AND_ALLOWA2

ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Accounts, Notes, Loans and Financing Receivable	'	'
Accounts receivable, net	$2,171	$1,965
Continuing operations	'	'
Accounts, Notes, Loans and Financing Receivable	'	'
Patient accounts receivable	2,949	2,537
Allowance for doubtful accounts	-753	-589
Estimated future recoveries from accounts assigned to our collection agency subsidiary	90	91
Net cost reports and settlements receivable (payable) and valuation allowances	-118	-77
Accounts receivable, net	2,168	1,962
Discontinued operations	'	'
Accounts, Notes, Loans and Financing Receivable	'	'
Accounts receivable, net	$3	$3

ACCOUNTS_RECEIVABLE_AND_ALLOWA3

ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS (Details 2) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Accounts, Notes, Loans and Financing Receivable	'	'	'	'	'
Allowance for doubtful accounts as a percent of patients accounts receivable	'	'	25.50%	'	23.20%
Self-Pay Patients	'	'	'	'	'
Accounts, Notes, Loans and Financing Receivable	'	'	'	'	'
Allowance for doubtful accounts as a percent of patients accounts receivable	'	'	76.50%	'	75.90%
Estimated costs of caring	$167	$122	$353	$226	'
Managed Care Patients	'	'	'	'	'
Accounts, Notes, Loans and Financing Receivable	'	'	'	'	'
Allowance for doubtful accounts as a percent of patients accounts receivable	'	'	5.70%	'	5.60%
Charity Care Patients	'	'	'	'	'
Accounts, Notes, Loans and Financing Receivable	'	'	'	'	'
Estimated costs of caring	55	31	95	63	'
Disproportionate Share Hospital	'	'	'	'	'
Accounts, Notes, Loans and Financing Receivable	'	'	'	'	'
Estimated costs of caring	$157	$119	$311	$186	'

DISCONTINUED_OPERATIONS_Detail

DISCONTINUED OPERATIONS (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Net operating revenues and income (loss) before income taxes	'	'	'	'
Net operating revenues	$0	$0	$1	$3
Income (loss) before income taxes	-25	6	-33	3
Litigation and investigation costs allocable to the previously divested hospitals related to a class action lawsuit	-18	'	'	'
Land	'	'	'	'
Discontinued Operations	'	'	'	'
Gain on sale of discontinued operations	'	$7	'	'

IMPAIRMENT_AND_RESTRUCTURING_C1

IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS (Details) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
	segment
IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS	'	'
Net impairment and restructuring charges and acquisition-related costs	$53	$25
Impairment of property	'	2
Restructuring costs	18	7
Employee severance costs	9	5
Lease termination costs	'	1
Acquisition costs	26	10
Acquisition-related transaction costs	4	'
Acquisition integration charges	$22	'
Number of continuing operating segments	2	'

LONGTERM_DEBT_AND_LEASE_OBLIGA2

LONG-TERM DEBT AND LEASE OBLIGATIONS (Details) (USD $)

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Mar. 31, 2014

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

In Millions, unless otherwise specified

9 7/8%, due 2014

9 7/8%, due 2014

9 1/4%, due 2015

9 1/4%, due 2015

5%, due 2019

5%, due 2019

6 3/4%, due 2020

6 3/4%, due 2020

8%, due 2020

8%, due 2020

8 1/8%, due 2022

8 1/8%, due 2022

6 7/8%, due 2031

6 7/8%, due 2031

6 1/4%, due 2018

6 1/4%, due 2018

4 3/4%, due 2020

4 3/4%, due 2020

6%, due 2020

6%, due 2020

4 1/2%, due 2021

4 1/2%, due 2021

4 3/8%, due 2021

4 3/8%, due 2021

Credit Facility due 2016

Credit Facility due 2016

LONG-TERM DEBT AND LEASE OBLIGATIONS

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest rate, stated percentage

'

'

9.88%

9.88%

9.25%

9.25%

5.00%

5.00%

6.75%

6.75%

8.00%

8.00%

8.13%

8.13%

6.88%

6.88%

6.25%

6.25%

4.75%

4.75%

6.00%

6.00%

4.50%

4.50%

4.38%

4.38%

'

'

Carrying amount

'

'

$60

$60

$474

$474

$1,100

'

$300

$300

$750

$750

$2,800

$2,800

$430

$430

$1,041

$1,041

$500

$500

$1,800

$1,800

$850

$850

$1,050

$1,050

$0

$405

Capital leases and mortgage notes

428

407

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unamortized note discounts and premium

-19

-28

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total long-term debt

11,564

10,839

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Less current portion

622

149

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long-term debt, net of current portion

$10,942

$10,690

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

LONGTERM_DEBT_AND_LEASE_OBLIGA3

LONG-TERM DEBT AND LEASE OBLIGATIONS (Details 2) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Mar. 07, 2014
LONG-TERM DEBT AND LEASE OBLIGATIONS	'	'
Secured debt to EBITDA ratio	3	'
Interest rate on borrowings (as a percent)	1.88%	'
Issuance fee (percentage)	0.13%	'
Credit Agreement	'	'
LONG-TERM DEBT AND LEASE OBLIGATIONS	'	'
Revolving credit facility, maximum borrowing capacity	$1,000	'
Line of credit facility, subfacility maximum available capacity	300	'
Outstanding cash borrowings	0	'
Standby letters of credit outstanding	6	'
Amount available for borrowing under revolving credit facility	994	'
Credit Agreement | Low end of range	'	'
LONG-TERM DEBT AND LEASE OBLIGATIONS	'	'
Unused commitment fee (as a percent)	0.38%	'
Credit Agreement | High end of range	'	'
LONG-TERM DEBT AND LEASE OBLIGATIONS	'	'
Unused commitment fee (as a percent)	0.50%	'
Credit Agreement | Base rate	'	'
LONG-TERM DEBT AND LEASE OBLIGATIONS	'	'
Base rate used to calculate interest rate	'base rate	'
Credit Agreement | Base rate | Low end of range	'	'
LONG-TERM DEBT AND LEASE OBLIGATIONS	'	'
Margin on variable rate (as a percent)	1.00%	'
Credit Agreement | Base rate | High end of range	'	'
LONG-TERM DEBT AND LEASE OBLIGATIONS	'	'
Margin on variable rate (as a percent)	1.50%	'
Credit Agreement | LIBOR	'	'
LONG-TERM DEBT AND LEASE OBLIGATIONS	'	'
Base rate used to calculate interest rate	'LIBOR	'
Credit Agreement | LIBOR | Low end of range	'	'
LONG-TERM DEBT AND LEASE OBLIGATIONS	'	'
Margin on variable rate (as a percent)	2.00%	'
Credit Agreement | LIBOR | High end of range	'	'
LONG-TERM DEBT AND LEASE OBLIGATIONS	'	'
Margin on variable rate (as a percent)	2.50%	'
Letter of Credit Facility	'	'
LONG-TERM DEBT AND LEASE OBLIGATIONS	'	'
Revolving credit facility, maximum borrowing capacity	'	180
Base rate used to calculate interest rate	'base rate	'
Margin on variable rate (as a percent)	0.88%	'
Unused commitment fee (as a percent)	0.50%	'
Standby letters of credit outstanding	133	'
Borrowing capacity after increase subject to certain conditions	'	$200
Letter of Credit Facility | High end of range	'	'
LONG-TERM DEBT AND LEASE OBLIGATIONS	'	'
Number of business days after notice, for reimbursement of amount drawn.	'3 days	'
Unused commitment fee after step down	0.38%	'

LONGTERM_DEBT_AND_LEASE_OBLIGA4

LONG-TERM DEBT AND LEASE OBLIGATIONS (Details 3) (5%, due 2015, USD $)	Jun. 30, 2014	Mar. 31, 2014
In Millions, unless otherwise specified
5%, due 2015	'	'
LONG-TERM DEBT AND LEASE OBLIGATIONS	'	'
Aggregate principal amount of notes sold	$500	$600

GUARANTEES_Details

GUARANTEES (Details) (USD $)	Jun. 30, 2014
In Millions, unless otherwise specified
Income and Revenue Collection Guarantee	'
GUARANTEES	'
Maximum potential amount of future payments under guarantees	$94
Liability for the fair value of guarantees	69
Guaranteed Minimum Rent	'
GUARANTEES	'
Maximum potential amount of future payments under guarantees	4
Guaranteed Minimum Rent | Maximum	'
GUARANTEES	'
Liability for the fair value of guarantees	$1

EMPLOYEE_BENEFIT_PLANS_Details

EMPLOYEE BENEFIT PLANS (Details) (USD $)	6 Months Ended
In Millions, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Continuing operations	'	'
EMPLOYEE BENEFIT PLANS	'	'
Stock-based compensation costs, pretax	$26	$22
Restricted Stock Units	'	'
EMPLOYEE BENEFIT PLANS	'	'
Contractual right to receive shares of common stock for a stock based award	1	'
Portion of awards vesting on each of the first three anniversary dates of the grant (as a percent)	33.00%	'
Vesting period	'3 years	'
2008 Stock Incentive Plan	'	'
EMPLOYEE BENEFIT PLANS	'	'
Shares available for issuance under the plan	6,000,000	'
2008 Stock Incentive Plan | Stock Options	'	'
EMPLOYEE BENEFIT PLANS	'	'
Expiration period from the date of grant	'	'5 years
Vesting period	'	'3 years

EMPLOYEE_BENEFIT_PLANS_Details1

EMPLOYEE BENEFIT PLANS (Details 2) (USD $)	6 Months Ended
In Millions, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
	item
Stock option activity	'	'
Granted (in shares)	0	'
Stock Options	'	'
Stock option activity	'	'
Outstanding at the beginning of the period (in shares)	3,308,111	'
Granted (in shares)	0	'
Exercised (in shares)	-336,789	-875,005
Forfeited/Expired (in shares)	-620,719	'
Outstanding at the end of the period (in shares)	2,350,603	'
Vested and expected to vest at the end of the period (in shares)	2,340,428	'
Exercisable at the end of the period (in shares)	1,932,972	'
Weighted Average Exercise Price Per Share	'	'
Outstanding at the beginning of the period (in dollars per share)	$30.79	'
Exercised (in dollars per share)	$34.08	'
Forfeited/Expired (in dollars per share)	$47.96	'
Outstanding at the end of the period (in dollars per share)	$25.78	'
Vested and expected to vest at the end of the period (in dollars per share)	$25.73	'
Exercisable at the end of the period (in dollars per share)	$24.03	'
Aggregate Intrinsic Value	'	'
Outstanding at the end of the period	$50	'
Vested and expected to vest at the end of the period	50	'
Exercisable at the end of the period	44	'
Weighted Average Remaining Life	'	'
Outstanding at the end of the period	'3 years 9 months 18 days	'
Vested and expected to vest at the end of the period	'3 years 9 months 18 days	'
Exercisable at the end of the period	'3 years 6 months	'
Other Disclosures	'	'
Aggregate Intrinsic value of awards exercised	4	16
Unrecognized compensation costs	$3	'
Period for recognition of unrecognized compensation costs	'1 year 3 months 18 days	'
Weighted average estimated fair value of awards granted (in dollars per share)	'	$14.46
Assumptions used to calculate fair value of awards granted to top eleven employees	'	'
Expected volatility (as a percent)	'	50.00%
Expected dividend yield (as a percent)	'	0.00%
Expected life	'	'3 years 7 months 6 days
Expected forfeiture rate (as a percent)	'	6.00%
Risk-free interest rate (as a percent)	'	0.48%
Early exercise threshold gain (as a percent)	'	100.00%
Early exercise rate, gain (as a percent)	'	50.00%
Number of years excluded from historical share-price volatility	2	'
Stock Options | 2008 Stock Incentive Plan	'	'
Stock option activity	'	'
Granted (in shares)	'	295,639
Other Disclosures	'	'
Vesting period	'	'3 years
Expiration period	'	'5 years

EMPLOYEE_BENEFIT_PLANS_Details2

EMPLOYEE BENEFIT PLANS (Details 3) (USD $)	6 Months Ended
	Jun. 30, 2014
Options Exercisable	'
Number of Options Outstanding (in shares)	2,350,603
Number of Options Exercisable (in shares)	1,932,972
Weighted Average Remaining Contractual life	'3 years 9 months 18 days
Weighted Average Exercise Price Outstanding (in dollars per share)	$25.78
Weighted Average Exercise Price (in dollars per share)	$24.03
Stock Options | Range of Exercise Prices, $0.00 to $4.569	'
Summary information about outstanding stock options	'
Exercise price per share, low end of the range (in dollars per share)	$0
Exercise price per share, high end of the range (in dollars per share)	$4.57
Options Exercisable	'
Number of Options Outstanding (in shares)	279,719
Number of Options Exercisable (in shares)	279,719
Weighted Average Remaining Contractual life	'4 years 7 months 6 days
Weighted Average Exercise Price Outstanding (in dollars per share)	$4.56
Weighted Average Exercise Price (in dollars per share)	$4.56
Stock Options | Range of Exercise Prices, $4.57 to $25.089	'
Summary information about outstanding stock options	'
Exercise price per share, low end of the range (in dollars per share)	$4.57
Exercise price per share, high end of the range (in dollars per share)	$25.09
Options Exercisable	'
Number of Options Outstanding (in shares)	1,010,431
Number of Options Exercisable (in shares)	871,251
Weighted Average Remaining Contractual life	'5 years 4 months 24 days
Weighted Average Exercise Price Outstanding (in dollars per share)	$20.89
Weighted Average Exercise Price (in dollars per share)	$20.55
Stock Options | Range of Exercise Prices, $25.09 to $32.569	'
Summary information about outstanding stock options	'
Exercise price per share, low end of the range (in dollars per share)	$25.09
Exercise price per share, high end of the range (in dollars per share)	$32.57
Options Exercisable	'
Number of Options Outstanding (in shares)	453,862
Number of Options Exercisable (in shares)	453,862
Weighted Average Remaining Contractual life	'2 years 1 month 6 days
Weighted Average Exercise Price Outstanding (in dollars per share)	$29.38
Weighted Average Exercise Price (in dollars per share)	$29.38
Stock Options | Range of Exercise Prices, $32.57 to $42.529	'
Summary information about outstanding stock options	'
Exercise price per share, low end of the range (in dollars per share)	$32.57
Exercise price per share, high end of the range (in dollars per share)	$42.53
Options Exercisable	'
Number of Options Outstanding (in shares)	595,009
Number of Options Exercisable (in shares)	316,558
Weighted Average Remaining Contractual life	'2 years 1 month 6 days
Weighted Average Exercise Price Outstanding (in dollars per share)	$40.87
Weighted Average Exercise Price (in dollars per share)	$42.24
Stock Options | Range of Exercise Prices, $42.53 to $55.129	'
Summary information about outstanding stock options	'
Exercise price per share, low end of the range (in dollars per share)	$42.53
Exercise price per share, high end of the range (in dollars per share)	$55.13
Options Exercisable	'
Number of Options Outstanding (in shares)	11,582
Number of Options Exercisable (in shares)	11,582
Weighted Average Remaining Contractual life	'8 months 12 days
Weighted Average Exercise Price Outstanding (in dollars per share)	$49.17
Weighted Average Exercise Price (in dollars per share)	$49.17

EMPLOYEE_BENEFIT_PLANS_Details3

EMPLOYEE BENEFIT PLANS (Details 4) (Restricted Stock Units, USD $)	6 Months Ended		12 Months Ended
In Millions, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Restricted stock unit activity	'	'	'
Unvested at the beginning of the period (in shares)	2,707,222	'	'
Granted (in shares)	1,280,028	'	'
Vested (in shares)	-884,431	'	'
Forfeited (in shares)	-119,020	'	'
Unvested at the end of the period (in shares)	2,983,799	'	'
Weighted Average Grant Date Fair Value Per Unit	'	'	'
Unvested at the beginning of the period (in dollars per share)	33.34	'	'
Granted (in dollars per share)	44.36	'	'
Vested (in dollars per share)	30.18	'	'
Forfeited (in dollars per share)	33.68	'	'
Unvested at the end of the period (in dollars per share)	38.04	'	'
Other Disclosures	'	'	'
Granted (in shares)	1,280,028	'	'
Vesting period	'3 years	'	'
Awards vesting (as a percent)	33.00%	'	'
Unrecognized compensation costs	94	'	'
Period for recognition of unrecognized compensation costs	'2 years 7 months 6 days	'	'
Chief executive officer	'	'	'
Restricted stock unit activity	'	'	'
Granted (in shares)	'	212,180	'
Other Disclosures	'	'	'
Granted (in shares)	'	212,180	'
Time-vesting	'	'	'
Restricted stock unit activity	'	'	'
Granted (in shares)	1,280,028	804,062	'
Other Disclosures	'	'	'
Restricted stock that will vest and be settled over a three-year period from the grant date (in shares)	944,590	723,929	'
Restricted stock that will vest and be settled on the fifth anniversary of the grant date (in shares)	52,971	80,133	'
Percentage of restricted stock units, which will vest on the fifth anniversary of the grant date	100.00%	100.00%	'
Restricted stock that will vest and be settled on the third anniversary of the grant date (in shares)	10,652	'	'
Percentage of restricted stock units, which will vest on the third anniversary of the grant date	100.00%	'	'
Granted (in shares)	1,280,028	804,062	'
Percentage of restricted stock units, which will vest three years from the grant date	100.00%	'	'
Vesting period	'3 years	'3 years	'
Time-vesting | Chief executive officer	'	'	'
Restricted stock unit activity	'	'	'
Granted (in shares)	'	106,090	'
Other Disclosures	'	'	'
Granted (in shares)	'	106,090	'
Performance-based vesting	'	'	'
Restricted stock unit activity	'	'	'
Granted (in shares)	271,815	206,058	'
Other Disclosures	'	'	'
Granted (in shares)	271,815	206,058	'
Term for achievement of specified performance goal	'1 year	'	'
Percentage of restricted stock units, which will vest three years from the grant date	'	'	100.00%
Vesting period	'3 years	'3 years	'
Performance-based vesting | Chief executive officer	'	'	'
Restricted stock unit activity	'	'	'
Granted (in shares)	'	106,090	'
Other Disclosures	'	'	'
Granted (in shares)	'	106,090	'
Performance-based vesting | Minimum	'	'	'
Other Disclosures	'	'	'
Awards vesting (as a percent)	0.00%	'	'
Performance-based vesting | Maximum	'	'	'
Other Disclosures	'	'	'
Awards vesting (as a percent)	200.00%	'	'
Performance-based vesting, one | Chief executive officer	'	'	'
Other Disclosures	'	'	'
Vesting period	'	'3 years	'
Awards vesting (as a percent)	'	50.00%	'
Performance-based vesting, two | Chief executive officer	'	'	'
Other Disclosures	'	'	'
Vesting period	'	'6 years	'
Awards vesting (as a percent)	'	50.00%	'

EQUITY_Details

EQUITY (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, except Share data in Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Changes in Shareholders' Equity	'	'	'	'
Balances	'	'	$878	$1,218
Net income (loss)	-7	-43	-23	-126
Distributions paid to noncontrolling interests	'	'	-18	-10
Contributions from noncontrolling interests	'	'	3	'
Other comprehensive income	3	0	4	0
Sales of joint venture interests	'	'	'	53
Purchases of businesses or joint venture interests	'	'	29	13
Repurchase of common stock	'	'	'	-192
Stock-based compensation expense and issuance of common stock	'	'	22	29
Balances	873	981	873	981
Common Stock	'	'	'	'
Changes in Shareholders' Equity	'	'	'	'
Balances	'	'	7	7
Balances (in shares)	'	'	96,860	104,633
Net income (loss)	'	'	0	0
Distributions paid to noncontrolling interests	'	'	0	0
Contributions from noncontrolling interests	'	'	0	'
Other comprehensive income	'	'	0	'
Sales of joint venture interests	'	'	'	0
Purchases of businesses or joint venture interests	'	'	0	0
Purchases of businesses or joint venture interests (in shares)	'	'	0	0
Repurchase of common stock	'	'	'	0
Repurchase of common stock (in shares)	'	'	0	-4,453
Stock-based compensation expense and issuance of common stock	'	'	0	0
Stock-based compensation expense and issuance of common stock (in shares)	'	'	954	1,558
Balances	7	7	7	7
Balances (in shares)	97,814	101,738	97,814	101,738
Additional Paid-in Capital	'	'	'	'
Changes in Shareholders' Equity	'	'	'	'
Balances	'	'	4,572	4,471
Net income (loss)	'	'	0	0
Distributions paid to noncontrolling interests	'	'	0	0
Contributions from noncontrolling interests	'	'	0	'
Other comprehensive income	'	'	0	'
Sales of joint venture interests	'	'	'	53
Purchases of businesses or joint venture interests	'	'	0	0
Repurchase of common stock	'	'	'	0
Stock-based compensation expense and issuance of common stock	'	'	22	28
Balances	4,594	4,552	4,594	4,552
Accumulated Other Comprehensive Loss	'	'	'	'
Changes in Shareholders' Equity	'	'	'	'
Balances	'	'	-24	-68
Net income (loss)	'	'	0	0
Distributions paid to noncontrolling interests	'	'	0	0
Contributions from noncontrolling interests	'	'	0	'
Other comprehensive income	'	'	4	'
Sales of joint venture interests	'	'	'	0
Purchases of businesses or joint venture interests	'	'	0	0
Repurchase of common stock	'	'	'	0
Stock-based compensation expense and issuance of common stock	'	'	0	0
Balances	-20	-68	-20	-68
Accumulated Deficit	'	'	'	'
Changes in Shareholders' Equity	'	'	'	'
Balances	'	'	-1,422	-1,288
Net income (loss)	'	'	-58	-138
Distributions paid to noncontrolling interests	'	'	0	0
Contributions from noncontrolling interests	'	'	0	'
Other comprehensive income	'	'	0	'
Sales of joint venture interests	'	'	'	0
Purchases of businesses or joint venture interests	'	'	0	0
Repurchase of common stock	'	'	'	0
Stock-based compensation expense and issuance of common stock	'	'	0	0
Balances	-1,480	-1,426	-1,480	-1,426
Treasury Stock	'	'	'	'
Changes in Shareholders' Equity	'	'	'	'
Balances	'	'	-2,378	-1,979
Net income (loss)	'	'	0	0
Distributions paid to noncontrolling interests	'	'	0	0
Contributions from noncontrolling interests	'	'	0	'
Other comprehensive income	'	'	0	'
Sales of joint venture interests	'	'	'	0
Purchases of businesses or joint venture interests	'	'	0	0
Repurchase of common stock	'	'	'	-192
Stock-based compensation expense and issuance of common stock	'	'	0	1
Balances	-2,378	-2,170	-2,378	-2,170
Noncontrolling Interests	'	'	'	'
Changes in Shareholders' Equity	'	'	'	'
Balances	'	'	123	75
Net income (loss)	'	'	13	8
Distributions paid to noncontrolling interests	'	'	-18	-10
Contributions from noncontrolling interests	'	'	3	'
Other comprehensive income	'	'	0	'
Sales of joint venture interests	'	'	'	0
Purchases of businesses or joint venture interests	'	'	29	13
Repurchase of common stock	'	'	'	0
Stock-based compensation expense and issuance of common stock	'	'	0	0
Balances	$150	$86	$150	$86

EQUITY_Details_2

EQUITY (Details 2) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Changes in redeemable noncontrolling interests in equity of consolidated subsidiaries	'	'
Distributions paid to noncontrolling interests	($18)	($10)
Contributions from noncontrolling interests	3	'
Redeemable noncontrolling interests	'	'
Changes in redeemable noncontrolling interests in equity of consolidated subsidiaries	'	'
Balances at beginning of period	247	16
Net income	22	4
Distributions paid to noncontrolling interests	-2	0
Contributions from noncontrolling interests	10	0
Sales of joint venture interests	0	50
Purchases of businesses	0	10
Balances at end of period	$277	$80

PROPERTY_AND_PROFESSIONAL_AND_1

PROPERTY AND PROFESSIONAL AND GENERAL LIABILITY INSURANCE (Details) (USD $)	6 Months Ended			12 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Dec. 31, 2013
			Professional and General Liability Insurance	Professional and General Liability Insurance
Insurance coverage	'	'	'	'
Self insurance reserve	'	'	$729	$699
Loss contingency, discount rate maturity (in years)	'	'	'P7Y	'P7Y
Risk-free rate (as a percent)	'	'	2.13%	2.45%
Malpractice expense	$127	$52	'	'

CLAIMS_AND_LAWSUITS_Details

CLAIMS AND LAWSUITS (Details) (USD $)

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2013

Dec. 31, 2012

Jun. 30, 2014

Jun. 30, 2014

Jan. 31, 2013

Jun. 30, 2014

Jul. 31, 2010

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Governmental Reviews

Governmental Reviews

Kyphoplasty

Kyphoplasty

Kyphoplasty

ICD

Ordinary Course Matters

Ordinary Course Matters

item

item

item

item

person

Minimum

item

person

Loss Contingencies

'

'

'

'

'

'

'

'

'

'

'

'

Number of hospitals under governmental review

'

'

'

'

'

'

'

'

7

56

'

'

Settlement amount

'

'

'

'

'

'

$900,000

'

'

'

'

'

Number of hospitals not under investigation

'

'

'

'

'

'

'

1

'

'

'

'

Number of hospitals for which settlement discussions to resolve matter is engaged

'

'

'

'

'

'

'

5

'

'

'

'

Number of defendants

'

'

'

'

'

4

'

'

'

'

'

'

Increase in litigation reserve

'

'

'

'

10,000,000

'

'

'

'

'

'

'

Litigation reserve

64,000,000

46,000,000

9,000,000

10,000,000

38,000,000

38,000,000

'

'

'

'

'

'

Number of persons in court certified class action lawsuits

'

'

'

'

'

'

'

'

'

'

'

5,000

Number of persons identified in class certification process

'

'

'

'

'

'

'

'

'

'

8

'

Number of plaintiffs identified in class certification process

'

'

'

'

'

'

'

'

'

'

2

'

Maximum potential payment

'

'

'

'

'

'

'

'

'

'

32,500,000

'

Reserves for hurricane Katrina related lawsuits

'

'

'

'

'

'

'

'

'

'

$17,000,000

'

CLAIMS_AND_LAWSUITS_Details_2

CLAIMS AND LAWSUITS (Details 2) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Loss Contingencies	'	'
Litigation reserve, Balances at Beginning of Period	$46	$10
Litigation and Investigation costs	33	2
Cash Payments	-12	-3
Other	-3	0
Litigation reserve, Balances at End of Period	64	9
Claims, lawsuits, and regulatory proceedings | Continuing operations	'	'
Loss Contingencies	'	'
Litigation reserve, Balances at Beginning of Period	40	5
Litigation and Investigation costs	15	2
Cash Payments	-6	-2
Other	-3	0
Litigation reserve, Balances at End of Period	46	5
Claims, lawsuits, and regulatory proceedings | Discontinued operations	'	'
Loss Contingencies	'	'
Litigation reserve, Balances at Beginning of Period	6	5
Litigation and Investigation costs	18	0
Cash Payments	-6	-1
Other	0	0
Litigation reserve, Balances at End of Period	$18	$4

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Income Taxes	'	'	'	'
Income tax expenses	$8	($20)	$7	($73)
Income tax expense related to increase in the valuation allowance for deferred tax assets	'	'	3	'
Unrecognized tax benefits	43	'	43	'
Unrecognized federal and state tax benefits and reserves for interest and penalties, which may decrease in the next 12 months	1	'	1	'
Interest and penalties related to accrued liabilities for uncertain tax positions, recognized	'	'	0	'
Continuing operations	'	'	'	'
Income Taxes	'	'	'	'
Unrecognized tax benefits which, if recognized, would impact effective tax rate	34	'	34	'
Total accrued interest and penalties on unrecognized tax benefits	$5	'	$5	'

EARNINGS_LOSS_PER_COMMON_SHARE2

EARNINGS (LOSS) PER COMMON SHARE (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, except Share data in Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
EARNINGS (LOSS) PER COMMON SHARE	'	'	'	'
Net loss attributable to Tenet Healthcare Corporation common shareholders for basic earnings per share	($10)	($53)	($37)	($139)
Net loss attributable to Tenet Healthcare Corporation common shareholders for basic earnings per share (in Weighted Average Shares)	97,677	103,010	97,419	103,557
Net loss attributable to Tenet Healthcare Corporation common shareholders for basic earnings, Per-Share Amount (in dollars per share)	($0.11)	($0.52)	($0.38)	($1.34)
Effect of dilutive stock options and restricted stock units	0	0	0	0
Effect of dilutive stock options and restricted stock units (in Weighted Average Shares)	0	0	0	0
Effect of dilutive stock options and restricted stock units (Per-Share)	$0	$0	$0	$0
Net loss attributable to Tenet Healthcare Corporation common shareholders for diluted earnings per share	($10)	($53)	($37)	($139)
Net loss attributable to Tenet Healthcare Corporation common shareholders for diluted earnings per share (in Weighted Average Shares)	97,677	103,010	97,419	103,557
Net loss attributable to Tenet Healthcare Corporation common shareholders for diluted earnings per share, Per-Share Amount (in dollars per share)	($0.11)	($0.52)	($0.38)	($1.34)
Effect of employee stock options, restricted stock units and deferred compensation units on the diluted shares	2,123	2,326	2,053	2,282

FAIR_VALUE_MEASUREMENTS_Detail

FAIR VALUE MEASUREMENTS (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Fair value of assets and liabilities measured on recurring basis	'	'
Marketable securities-current	$2	$1
Investments in Reserve Yield Plus Fund	2	2
Marketable debt securities-noncurrent	66	62
Investments	70	65
Estimated fair value of the long-term debt instrument as a percentage of carrying value	107.60%	103.50%
Recurring basis | Quoted Prices in Active Markets for Identical Assets (Level 1)	'	'
Fair value of assets and liabilities measured on recurring basis	'	'
Marketable securities-current	2	1
Investments in Reserve Yield Plus Fund	0	0
Marketable debt securities-noncurrent	27	23
Investments	29	24
Recurring basis | Significant Other Observable Inputs (Level 2)	'	'
Fair value of assets and liabilities measured on recurring basis	'	'
Marketable securities-current	0	0
Investments in Reserve Yield Plus Fund	2	2
Marketable debt securities-noncurrent	38	38
Investments	40	40
Recurring basis | Significant Unobservable Inputs (Level 3)	'	'
Fair value of assets and liabilities measured on recurring basis	'	'
Marketable securities-current	0	0
Investments in Reserve Yield Plus Fund	0	0
Marketable debt securities-noncurrent	1	1
Investments	$1	$1

ACQUISITIONS_Details

ACQUISITIONS (Details) (USD $)	6 Months Ended		6 Months Ended				3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
			Series of individual business acquisition	Ambulatory Surgery Centers	Urgent care centers	Texas Regional Medical Center	Vanguard	Vanguard	Vanguard	Vanguard
				item	item	item
Business Acquisition	'	'	'	'	'	'	'	'	'	'
Number of ambulatory surgery centers	'	'	'	3	'	'	'	'	'	'
Number of urgent care centers	'	'	'	'	3	'	'	'	'	'
Number of licensed beds	'	'	'	'	'	70	'	'	'	'
Goodwill increased due to adjustments to purchase price allocations	'	'	$87	'	'	'	'	'	'	'
Preliminary purchase price allocations	'	'	'	'	'	'	'	'	'	'
Current assets	'	'	14	'	'	'	'	'	'	'
Property and equipment	'	'	19	'	'	'	'	'	'	'
Goodwill	3,200	3,042	71	'	'	'	'	'	'	'
Current liabilities	'	'	-16	'	'	'	'	'	'	'
Long-term liabilities	'	'	-17	'	'	'	'	'	'	'
Noncontrolling interests	'	'	-29	'	'	'	'	'	'	'
Net cash paid	'	'	42	'	'	'	'	'	'	'
Transaction costs related to prospective and closed acquisitions	4	'	'	'	'	'	'	'	'	'
Pro Forma Information - Unaudited	'	'	'	'	'	'	'	'	'	'
Net operating revenues	'	'	'	'	'	'	4,042	3,940	7,968	7,826
Income (loss) from continuing operations, before income taxes	'	'	'	'	'	'	$17	($66)	$5	($198)

SEGMENT_INFORMATION_Details

SEGMENT INFORMATION (Details) (USD $)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
			item
SEGMENT INFORMATION	'	'	'	'	'
Number of hospitals owned by subsidiaries	'	'	79	'	'
Number of licensed beds in hospitals operated by subsidiaries	'	'	20,553	'	'
Number of provider-based outpatient centers operated by subsidiaries	'	'	189	'	'
Number of health plans	'	'	6	'	'
SEGMENT INFORMATION	'	'	'	'	'
Assets	$16,907	'	$16,907	'	$16,130
Capital expenditures	242	123	523	256	'
Net operating revenues	4,042	2,422	7,968	4,809	'
Adjusted EBITDA	460	336	847	610	'
Depreciation and amortization	209	121	402	235	'
Adjusted EBITDA	'	'	'	'	'
Impairment and restructuring charges, and acquisition-related costs	-32	-11	-53	-25	'
Litigation and investigation costs	-12	-2	-15	-2	'
Interest expense	-190	-98	-372	-201	'
Loss from early extinguishment of debt	0	-171	0	-348	'
Investment earnings	0	1	0	1	'
Income (loss) from continuing operations before income taxes	17	-66	5	-200	'
Hospital operations and other	'	'	'	'	'
SEGMENT INFORMATION	'	'	'	'	'
Assets	16,577	'	16,577	'	15,874
Capital expenditures	237	117	510	248	'
Adjusted EBITDA	416	308	755	550	'
Depreciation and amortization	204	115	392	225	'
Conifer	'	'	'	'	'
SEGMENT INFORMATION	'	'	'	'	'
Assets	330	'	330	'	256
Capital expenditures	5	6	13	8	'
Adjusted EBITDA	44	28	92	60	'
Depreciation and amortization	5	6	10	10	'
Conifer | Minimum	'	'	'	'	'
SEGMENT INFORMATION	'	'	'	'	'
Number of Tenet and non-Tenet Hospitals and other health care organizations to which Conifer provided revenue cycle services	'	'	700	'	'
Operating segments	'	'	'	'	'
SEGMENT INFORMATION	'	'	'	'	'
Net operating revenues	4,180	2,516	8,246	4,995	'
Operating segments | Hospital operations and other	'	'	'	'	'
SEGMENT INFORMATION	'	'	'	'	'
Net operating revenues	3,895	2,297	7,676	4,565	'
Operating segments | Conifer | Tenet	'	'	'	'	'
SEGMENT INFORMATION	'	'	'	'	'
Net operating revenues	138	94	278	186	'
Operating segments | Conifer | Other customers	'	'	'	'	'
SEGMENT INFORMATION	'	'	'	'	'
Net operating revenues	147	125	292	244	'
Intercompany eliminations	'	'	'	'	'
SEGMENT INFORMATION	'	'	'	'	'
Net operating revenues	($138)	($94)	($278)	($186)	'

SEGMENT_INFORMATION_Details_2

SEGMENT INFORMATION (Details 2) (Tenet and Catholic Health Initiatives, Revenue, Customer, Conifer)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
	item
Tenet and Catholic Health Initiatives | Revenue | Customer | Conifer	'	'
SEGMENT INFORMATION	'	'
Number of customers	2	'
Percentage of concentration risk	82.00%	79.00%

SUBSEQUENT_EVENTS_Details

SUBSEQUENT EVENTS (Details) (USD $)	3 Months Ended		6 Months Ended							1 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Mar. 31, 2014	Jun. 30, 2014	Dec. 31, 2013	Jul. 31, 2014	Jul. 31, 2014
					5% senior notes due 2019	5% senior notes due 2019	9-1/4% senior notes due 2015	9-1/4% senior notes due 2015	Subsequent events	Subsequent events
									5% senior notes due 2019	9-1/4% senior notes due 2015
SUBSEQUENT EVENTS	'	'	'	'	'	'	'	'	'	'
Interest rate, stated percentage	'	'	'	'	5.00%	5.00%	9.25%	9.25%	5.00%	9.25%
Aggregate principal amount outstanding redeemed	'	'	'	'	'	'	'	'	'	$474
Loss from early extinguishment of debt	$0	($171)	$0	($348)	'	'	'	'	'	($24)